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Editorial
Readers of the UWOMJ will likely have noticed the absence of
new issues of the journal over the last two years. The reason, as I often
had the opportunity to explain to my fellow students, was the sad
imbalance between our production costs and quickly-shrinking budget.
The dissolution of our previous advertising partner – and principal
financial source – in mid-production left the journal short on funds and
scrambling to find alternative sources of income. Without sufficient
resources, the printing and distribution process could not move forward.
Yet this apparent dormancy on the part of journal publication
belies the enormous amount of activity and change which have taken place
“behind the scenes” during this period. The past year saw the launch of a
new updated website featuring a number of issues published exclusively
online. While perhaps less satisfying than seeing the journal in hard copy,
going online allowed us to clear the backlog of issues which had been long
ompleted but arrested at the printing stage. The editing process was also
improved with the reintroduction of the faculty-review process, whereby
student submissions were reviewed by faculty experts before coming to
print. This has helped to enhance the quality of articles, something which I
am confident will be evident to our readers. Most important, perhaps, has
been the renewed interest in the journal among first- and second-year
medical students, many of whom have contributed either through
submissions or by serving as editorial staff. Their hard work and creativity
have ensured the continuation of the journal as a viable, high-quality
publication.
It is this point which I especially hope to impress upon our
readers. The efforts of our editorial staff, in particular our Junior Associate
Editors, Wendy Ng and Amber Menezes, have reworked the production
process and allowed this issue to be printed. Yet the lack of committed
funds means that the journal remains in a precarious situation and that
future financial difficulties may once again put a halt to production. It
remains to our readers and the Faculty of Medicine at UWO to determine
the degree of support which the journal should receive.
On that note, I would sincerely like to thank the Department of
Paediatrics at the Schulich School of Medicine and Dentistry for their
financial donation to the journal, which helped to offset the cost of our
“Pediatrics” issue. I am also grateful for the support of our numerous
faculty reviewers who have contributed their time and expertise. Finally, I
would like to give special mention to Dr. Ronald Wexler, whose continued
interest in the UWOMJ since his own days as Editor during medical school
is truly a source of inspiration.
Sordid monetary matters aside, it has been a great pleasure and
privilege for me to serve as Editor-in-Chief of the UWOMJ. I am happy
and excited to give you the “Oncology” issue, and I hope that it may be the
beginning of a revived journal for many issues to come.
Sincerely,
Eisar Al-Sukhni
Editor-in-Chief
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The University of Western
Ontario Medical Journal
(UWOMJ) is Canada’s
second oldest student run
medical journal.
Established in 1930, the
UWOMJ provides a forum
for original articles based on
research or clinical medicine
of topic or historical interest.
It is a biannual publication
with interdisciplinary
readership that includes
students, faculty members,
residents and specialists. At
any given time during the
academic year, over 40 past
and present current medical
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Departmental Editors recruit,
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articles.
The UWOMJ has over 20
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reviewers for each issue,
often affiliated with the
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Medicine and Dentistry, as
well as hospitals in both
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For information about
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please follow the guidelines
outlined on our web site. The
UWOMJ is a facultyreviewed and peer-reviewed
publication. All editorial
matter in the UWOMJ
represents the opinions of
the authors and not
necessarily those of the
editorial staff and advisory
board. The editorial staff and
advisory council assume no
responsibility or liability for
damages arising from any
error or omission or from
use of any information or
advice contained in the
UWOMJ.
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Editorial

Oncology is a far-reaching specialty encompassing medicine and
surgery. In such a broad field, the issues that can be explored are
limitless. We would like to thank our authors and editors for their
research into the many different facets in this fascinating area. Their
hard work is reflected in the diversity and the depth of the articles
presented in this edition of the University of Western Ontario
Medical Journal. We would also like to thank the faculty reviewers
who have taken the time to offer feedback and mentorship to our
authors. Finally, we would also like to thank CU Advertising for
their assistance and support. This Oncology edition features articles
ranging from research to reviews to commentary and reflection. We
look forward to hearing your thoughts, suggestions and comments
for continual improvement.
After a brief hiatus from regular publications, we are extremely
proud to introduce our new Faculty Advisory Board. Furthermore,
we have established a new panel of faculty reviewers to aid us in
maintaining the high standards of the journal. It has been an honour
to work with and learn from faculty, as well as our fellow students
and future colleagues.

Oncology Issue Layout,
Formatting, Article
Management, Faculty
Review & Advisory Board
Recruitment &
Facilitation:
Wendy Ng,
Meds 2009
Front Cover Art:
“The Surgeons” by
Erin Dahlke,
Meds 2008.
Acrylic on canvas.
Back Cover Art:
Stained Glass by
Ian Turkstra,
Meds 2009
Background Collage by
Déanne Malenfant,
Meds 2009

With these new changes in place, we are excited for the future and
we look forward to bringing you more stimulating and thoughtprovoking pieces. The University of Western Ontario Medical
Journal's future has never looked better!

Layout Assistance:
Brent Mollon,
Meds 2010

Please write to us at uwomj@meds.uwo.ca with your feedback.

University of Western
Ontario Medical Journal

Sincerely,

Room MS-175
Medical Sciences Building
The University of Western
Ontario
London, ON
N6A 5C1

Wendy Ng and Amber Menezes
Junior Associate Editors

Web Site:
www.uwomeds.com/uwomj

For information about contributing written articles, art, photographs and other work to
the UWOMJ, please write to Wendy Ng, Managing Editor, at uwomj@meds.uwo.ca.
To volunteer as a Faculty Reviewer for the UWOMJ, please write to Wendy Ng,
Managing Editor, at uwomj@meds.uwo.ca.
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Diagnostic Review
Examining the Efficacy of Positron Emission Tomography (PET) in Cancer Diagnosis
Mark Kirchhof, Meds 2009
Jaron Jia Rong Chong, Meds 2010

Diagnostic imaging has become the cornerstone of cancer diagnosis. Over the
past twenty years, computed tomography (CT) has become the most widely
adopted imaging method for detection and staging of a variety of cancers.
However, there are many limitations to the use of CT in the diagnosis of
cancer. For example, CT does not have the ability to distinguish between
malignant and benign lesions. As such, functional imaging methods, such as
positron emission tomography (PET), has gained an increased following in the
medical community. PET allows clinicians to evaluate the functional
characteristics of tumours and is superior to CT in the staging of a variety of
cancers. Despite these benefits, the regulatory boards that govern the
healthcare system in Canada have been slow to adopt PET as a standard of care
due to some of the inherent limitations of the technology. New technology,
such as multi-modal imaging involving PET in combination with CT, will
undoubtedly address some of these inherent limitations. These developments
will continue to increase the pressure on healthcare administrators to reevaluate their positions on PET use in cancer care. Herein, we discuss some of
the benefits and limitations of PET use in cancer diagnosis.
This article has been reviewed by Dr. Jean-Luc Urbain.
Introduction
Positron Emission Tomography (PET) is playing an increasing role in the diagnosis and staging of
cancers since its development in 1973.1 However, the rate of adoption has not been equal throughout all
nations and technology uptake has been limited by the approval of funding authorities. In Canada, as of
June 2005, there is an installed base of 12 PET scanners, only 3 of which are available for clinical usage.2
This situation has created a dilemma for public health officials, nuclear medicine diagnosticians, and cancer
patients alike as the debate continues over the clinical utility of PET scanning. This review describes the
role of PET in oncology.
Positron Emission Tomography (PET)
Positron Emission Tomography (PET) is a medical imaging technique whereby a radioactive
tracing compound is administered to a patient and the resulting radiation emissions detected by a detection
array. These emissions are then analysed and reassembled into a three dimensional image of the target body
region.3 The radioactive tracing agents all emit positrons (positively-charged electrons). When this emitted
positron collides with a regular negatively-charged electron, two gamma rays are released at 180 degrees
apart from each other. The PET detector array surrounds the patient in the shape of a ring. When two
gamma rays are simultaneously detected on opposite sides of the ring, the trajectory of the rays can be
traced back to their origin. A single trajectory is insufficient to compile an image. However, over the course
of an acquisition, enough trajectories are detected to be analysed and compiled into an image.3 When these
radioactive tracing agents are manufactured, they usually come in the form of modified molecules
commonly found in the body. The most commonly used agent, [18F] fluorodeoxyglucose (FDG), is an
analog of glucose that cannot be metabolized by the body. FDG tends to accumulate in tumour cells with
higher metabolic rates, which uptake greater amounts of glucose. This allows for high-contrast
differentiation between tumours and normal tissues as well as more accurate diagnosis and staging,
especially with regards to metastasis.4,5
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Clinical and Economic Evidence Supporting Usage
The effectiveness of PET scanning in the diagnosis and staging of tumours has been strongly
established for several types of cancer, namely lung cancer, breast cancer, and colorectal cancer.6 Research
from Brink et al. found significant increases in the sensitivity of FDG-PET in detecting and staging smallcell lung cancer over conventional imaging methods.7 In breast cancer patients, FDG-PET was able to find
distant metastases in “30 % of patients who were thought only to have local-regional recurrence” ultimately
suggesting that PET may be useful for patients suspected of having tumour recurrence as well as
identifying distant sites of metastases.8 Also important in the treatment of breast cancer is axillary lymph
node staging, identified as a key factor in patient survival.9,10 While the majority of Stage I/II Canadian
breast cancer patients currently undergo axillary lymph node dissection as a diagnostic methodology, it has
been suggested that PET could offer a less invasive option. Similar results have been found using PET in
the initial diagnosis of colorectal cancers.11,12 Although PET performed similarly to X-Ray Computed
Tomography (CT) in the diagnosis of local lymph node involvement, PET was found to be superior to CT
in the detection of hepatic metastases, with significantly greater sensitivity (88% vs. 38%).11
Equally important to the usage of PET are issues of expense and cost-effectiveness. In an article
by Valk et al., the cost-effectiveness of whole-body PET staging of multiple cancers was determined with
the main finding being that surgical procedures averted through PET use resulted in savings ratios of 2:1 to
4:1.13 An economic analysis using PET for the work-up of pulmonary nodules and small-cell lung cancer
in Italy found an overall cost savings using PET with very high sensitivity (89% - 94%) and specificity
(80% - 100%).14 Canadian economic analysis confirms the cost-effectiveness of PET for staging for
cancers. In an Alberta study, the cost per scan was found to range from $1,231 if 3200 annual scans were
performed to $7,869 if 400 annual scans were performed, with a large portion of the cost coming from
regulatory requirements.15 These per scan costs represent a significant savings over current rates from the
United States. Research from Newfoundland found an estimated cost per PET study of $2,195 and that
each PET device would only require 740 cases per year to break even.6
Limitations of FDG-PET in Oncology
The major drawback in the use of PET is the prevalence of false-positives. The stomach, colon
and small intestine are capable of FDG uptake making it difficult to distinguish normal tissue from
neoplasms.16 In addition, since FDG is excreted via the urinary tract, intense accumulations of FDG can be
found in the kidney and bladder which can limit PET use in the evaluation in gynecologic malignancies as
well as exclude its use for detecting tumours of the bladder, local pelvic lymph nodes and prostate.17
Inflammation is another confounding process in the use of FDG-PET. This becomes particular
important in cancer patients that have been treated with chemotherapy or radiotherapy in which tissue
damage has occurred, and the possibility of inflammation is high which sometimes requires weeks to
months for healing before PET-FDG can be used.18,19 Related to the inflammation-based false-positives,
infections, such as tuberculosis, can result in elevated FDG uptake in local lymph nodes making it difficult
to differentiate between a lymph node neoplasm and immune cell proliferation20 Other forms of healing,
such as bone and joint processes, can also give false-positives. Healing bone can show FDG uptake for up
to 6 months after sustaining an injury.21,22 Degenerative joint disease can also show elevated FDG uptake
resulting in an intense, asymmetric signal that could be misdiagnosed as an osseous neoplasm.16
Another major problem area, in the use of PET in an oncology setting, relates to FDG-PET use in
endocrine tumours. Gastropancreatic neuroendocrine tumours have had limited detection success rates
such that only tumours that have very high proliferative rates and a low stage of differentiation have been
identified using FDG-PET.23 Hyperglycemia is another major limitation in the use of FDG-PET. This is
particularly prevalent in pancreatic tumours or small pancreatic masses in patients with diabetes mellitus.24
Finally, in patients with pheochromocytoma, a neuroendocrine tumour of the adrenal gland, FDG-PET is
incapable of distinguishing between the malignant form and the benign forms of the disease.25
The Future of PET
While FDG uptake is substantially higher in most types of tumours, there are many exceptions,
some of which have already been mentioned. Another drawback in the use of FDG as a tumour detecting
tracer is that it does not differentiate between specific types of cancer. As such, a variety of alternative
tracers are currently being investigated for their application in cancer therapy. These alternative tracers are
based on DNA analogs to detect rapidly proliferating cells, amino acid analogs that detect cells producing
higher levels of proteins and receptor agonists that allow for the identification of tumours expressing
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specific markers.26 A good example of this, is 18F -fluro-17-β-estradiol which binds to estrogen-receptor
positive breast cancer cells which, in this case, would alter the course of treatment for the cancer.27
Paralleling the development of these new tracers is the use of supplemental imaging technologies,
such as CT, in conjunction with PET. PET/CT produces better body maps in less time and as such the
higher initial equipment costs are offset by increased throughput.28 The improved anatomical localization
achieved using PET/CT can lead to improved diagnostic certainty, better biopsy guidance and ultimately
better treatment for the patient.28 The only major drawback of PET/CT is the increased dosage of radiation
the patient receives.29 Researchers have started to experiment with the possibility of PET/MRI since MRI
provides better anatomical information and excellent soft tissue contrast over CT with far less radiation
exposure. However, currently the detection technology used in PET scanners does not function well within
the magnetic field of the MRI machinery.30
Conclusion
The use of PET in the diagnosis of cancer has been a controversial topic among the medical
community in Canada. This review has touched upon some of the major arguments in this continuing
debate. It is apparent that PET usage in lung, breast and colorectal cancer has clear clinical advantages
over current imaging technologies. Combined with many studies that show the diagnostic value of PET in
these cancers actually decreases medical expenses, it becomes evident that the provincial governments
across Canada should adopt PET scans as a standard in patient care in these situations. Conversely, it
should be noted that PET is not an imaging panacea as there are many limitations in a variety of cancers.
With new tracers and new technologies, like PET/CT, it is expected that the breadth of diagnoses that can
be made with PET will increase. This will provide further impetus to examine the adoption of PET in more
medical centres across the country.
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Profiles
The Best of Both Worlds: The Clinician-Scientist
Renata Villela, Meds 2009
Dr. Fei-Fei Liu obtained her medical degree from the University of Toronto
and subsequently completed a fellowship at Stanford University. She returned
to Toronto to begin clinical work at Princess Margaret Hospital but found
herself delving into basic science research in her spare time. Over the years,
her research expanded and she became the principal investigator of her own
laboratory.
Whether seeing patients on her clinic days, focusing on her
research, or spending time with her family, Dr. Fei-Fei Liu’s optimism and
sense of humor carry her through the challenges of balancing her multi-faceted
career with her home life.
This article has been reviewed by Dr. Ken Harris.
Born in Taiwan, Dr. Fei-Fei Liu moved to Canada with her parents at the age of 8 and has been in
Toronto for most of her life. Her post-secondary education began with two years of undergraduate
coursework at the University of Toronto (U of T), followed by four years of medical school, also at the U
of T. She started her training in internal medicine and then further refined her interests by specializing in
radiation oncology.
Her love of basic sciences research was sparked during her fellowship at Stanford University in
1987 with the study of clinical hyperthermia. By 1988, Dr. Liu was on staff at Princess Margaret Hospital
(PMH) and was expected to devote all of her working hours to her clinical assignment. Nevertheless, she
arranged to pursue her new-found fascination with laboratory research on evenings and on weekends.
Given the lack of a model for a clinician-scientist at the time, the support of her mentors proved invaluable.
Because she did not pursue a Ph.D., Dr. Liu had to learn through experience the science and the art of
presenting meaningful data and of writing grants and manuscripts to secure peer-reviewed funding.
Ultimately, Dr. Liu’s hard work allowed her to diminish her clinical commitment to 20%, with the
remaining 80% of her intense work schedule being devoted to research. This mixture has proven fulfilling
for Dr. Liu, who values the creativity and the problem-solving aspects of research and the ability to
eventually translate the research findings into new ways of treating her patients. As the director of the U of
T’s Department of Radiation Oncology Fellowship Program, Dr. Liu has been able to use the knowledge
that she gained as a researcher and a physician to design a two-year, transdisciplinary, clinician-scientist
program of international stature for radiation medicine training.
From her career, Dr. Liu has learned that scientific accomplishments are mostly achieved through
hard work, passion, organization, and a competitive spirit, with luck also playing a role, albeit a minor one.
Recognizing opportunities and networking within the scientific community are also essential. Flexibility
and communication are likewise useful tools. Although Dr. Liu’s research began with the study of clinical
hyperthermia, she began to explore new avenues upon re-evaluation of the data. Therefore, it is important
to recognize the difference between perseverance and obstinacy. This distinction can mean the difference
between steadfastly pursuing a futile research path for the sake of not giving up versus believing in a
project that shows signs of long-term rewards.
Women often face unique challenges when pursuing an academic career in the basic sciences. At
the Department of Medical Biophysics, with which Dr. Liu is affiliated, she has observed that although
approximately half of all registered graduate students are female, this number declines as one progresses
from a Master’s degree to the Ph.D. stream. Further up in the hierarchy, there are only 12 female principal
investigators at the Ontario Cancer Institute (the research arm of the PMH) out of a total faculty of 68. Dr.
Liu speculates that the research environment tends not to be friendly towards women as they are often more
collaborative and conciliatory in nature, thereby focusing on a team-building approach. Meanwhile, men,
in general, focus more on individual accomplishments, which better complements the merit system in
academia. Because women are still the predominant caregivers in a family, those who begin to focus more
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time on their children may see career advancement opportunities evaporate as research productivity
declines. Clinical work appears to offer more flexibility for womenas possibly reflected in there being a
majority of female medical students at the U of Tbecause private practice offers the convenience of
control over hours devoted towards work versus family life.
In spite of these external forces, Dr. Liu is proof that building a career in research is not
impossible for women. She stresses the importance of finding a spousal partner who can support you and
your career choices and of being able to reciprocate this support, which involves continual work to build
and to maintain a strong marital relationship. Time management is the key to balancing the demands that
come from many different directions and to doing one’s best in all aspects of life. She believes that family
life provides the anchor for satisfying work. At the end of a stressful time at work, family is what provides
the strength to embrace a new day.
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Clinical Procedures
The Role of Gastrectomies in the Management of Gastric Cancer: an Overview
Brent Mollon, Meds 2010
This article has been reviewed by Dr. Neil Parry.
Introduction
Cancer of the stomach is considered to be a major cause of cancer death world wide, and is most
prevalent in Japan, China, Korea, Central Europe and Central/South America.1 In Canada, the projected
number of new cases and deaths in 2006 is estimated as 2800 and 1850, respectively.2 Thus, gastric cancer
is the 8th leading cause of cancer deaths in this country.2
The difference in prevalence of this disease between Canada and other countries is believed to be
partly due to diet. Foods high in carcinogenic compounds, like benzopyrene and N-nitroso compounds
found in smoked or preserved foods, are believed to be one of the causative factors of gastric cancers.1
Indeed, gastric cancer incidence in the United States has decreased fourfold since 1930, and has been
attributed to improved storage of food with decreased use of preservatives.1
Early gastric cancers are often asymptomatic, leading to late diagnosis in many cases.3 Symptoms,
once they develop, include weight loss, vomiting, an abdominal mass, indigestion, anorexia, and vague
epigastric pain.1 Endoscopic studies with biopsy are considered to be the gold standard procedure to
diagnose gastric cancers, although an upper-gastrointestinal X-ray series using a double contrast of air and
barium has been noted to detect 86.9% of lesions.1;3;4
Once the diagnosis of stomach cancer is made, the stage of the tumour should be established
through physical examination, computed tomography, and possibly laparoscopy.5 While the correct
approach to tumour staging is beyond the scope of this paper [see Reference 5 for summary of this
information], tumour stage is the primary determinant of therapy. For example, the location of the tumour,
the extent of lymph node involvement and the presence of metastatic sites all modify the operation which
will be undertaken.6 As a gastrectomy is believed to be the only curative treatment for this cancer7, this
article will focus on this procedure.
Gastric Cancer Resection
Gastrectomy
A curative gastrectomy refers to the removal of the stomach, which may be either partial (subtotal)
or complete (total), followed by reestablishment of the GI tract.6 Tissues are removed to allow for at least 5
cm margins from the tumour in order to ensure complete excision of the cancer. Intra-operative pathology
to prove cancer free margins is essential. The lymph nodes around the splenic artery are also removed and
attempts are undertaken to preserve the spleen. While the pancreas is not often removed, the greater
omentum along with the left gastric, celiac and common hepatic nodes are.6
Multiple reconstructive methods can be used to establish GI continuity, although the type of
gastrectomy (subtotal vs. total) will influence which one is performed. Sub-total gastrectomies, for
example, can be followed by either Billroth I, Billroth II, or Roux-en-Y gastrojejunostomy (see Figure 1).6
A Billroth II reconstruction is advantageous over as Billroth I as it removes the stomach (and anastomosis)
from the gastric bed, while a Roux-en-Y gastrojejunostomy prevents bile reflux. However, the Roux-en-Y
procedure will expose the intestinal mucosa to gastric secretions produced by the proximal stomach,
requiring the surgeon to either perform a truncal vagotomy or have the patient take proton-pump inhibitors
for life to prevent ulcerations. Total gastrectomies are classically followed by a Roux-en-Y
esophagojejunostomy reconstruction to connect the esophagus to the intestinal tract. Nonetheless, the
higher mortality associated with total gastrectomies compared to the subtotal procedure has lead to
surgeons proposing several modifications to the total gastrectomy in hopes of improved outcomes.6
Palliative gastrectomies are also performed to relieve symptoms, such as gastric outlet obstruction
or bleeding, of a patient with end-stage disease.8 While distally-located tumours may be resected, the poor
prognosis associated with surgery for advanced proximal tumours suggests that other measures, such as
bypass or venting gastrostomy tubes, should be undertaken for palliation.6

UWOMJ 76(1) 2007

- 13 -

Pre-Operative Considerations
Before undertaking a gastrectomy, a surgeon must first determine if a patient is able to tolerate the
operation and if the tumour is resectable.3 Pre-operative investigations should include a full pulmonary and
cardiovascular work-up. Computed tomography (CT scan) of the chest and abdomen are necessary to
determine the size and location of the tumour as well as any metastatic disease. One should also obtain
routine pre-operative blood work such as a complete blood count (to identify anemia), electrolyte panel,
BUN, creatinine, coagulation profile, and liver function tests. The following measures should enable a
surgeon to determine if an individual can tolerate surgery.3
Post-Operative Considerations
Once the procedure is complete, a surgeon should take steps to ensure that a patient achieves
adequate oral caloric intake while also evaluating the need for B12 injections due to the loss of intrinsic
factor.3 Lastly, the need for annual physical examination, blood work and imaging to identify any
metastases should be stressed to the patient as well as their family physician.3

Figure 1. A diagram of
the various reconstructive
methods available for
gastrectomies.3

Lymphadenectomies during Gastrectomies
When surgically resecting a tumour, it is also important to remove the lymph node drainage of the
tumour to limit metastatic spread. Lymphadenectomies for gastric cancers are classified as either D1, D2
or D3.8 D1 lymphadenectomies include the removal of the perigastric lymph nodes only. D2
lymphadenectomies remove the lymph nodes along left gastric, hepatic, celiac and splenic arteries in
addition to those in the splenic hilum and the perigastric regions, and D3 lymphadenectomies remove the
aforementioned nodes in addition to those within the porta hepatitis and periaortic regions.8 Numerically,
D2 lymphadenectomies remove an average of 27 nodes (range of 17-44), while the D3 procedures remove
an average of 43 (range of 25 to 64).9
How aggressive surgeons should be while conducting lymphadenectomies is an area of much
debate. Supporters of extensive lymphadenectomies note that these procedures should improve patient
outcomes by helping to ensure no positive lymph nodes are left in after the operation, while also enabling
physicians to more accurately stage the disease.8 This improved benefit has been noted in respective
reports.10 However, other researchers have noted that large randomized controlled trials have failed to
show any improvements in survival rates between D1 and D2, or D2 and D3 procedures.11;12
Despite such discrepancies in the literature, most researchers and organizations in North America
prefer D2 lymphadenectomies over D1 procedures.8 However, as surgeon experience is related to
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complications, it has been suggested that aggressive node dissection only be undertaken by surgeons who
have demonstrated sufficiently low patient morbidity and mortality rates. This would help ensure that the
benefits of extensive lymphadenectomies, if any, would not be overshadowed by an increased risk of
surgical complications.8
Conclusion
While the incidence of gastric cancers has decreased dramatically, it still remains the 8th leading
cause of death due to cancer in this country. This article explores what is considered to be the only known
curative treatment for this form of cancer, a gastrectomy, while also noting preoperative and postoperative
clinical considerations. While the debate about how extensive lymphadenectomies should be continues, the
size/location of the lesion in addition to surgeon experience appear to be the main determinants of whether
a D2 or D3 approach is most appropriate so as to limit surgical complications while maximizing clinical
benefit.
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Medicine and the Internet
Computing for Cancer: the role of distributed computing in cancer research
Samuel Krausz, Meds 2009
Jordan Glicksman, Meds 2010
Computers have always been used in medicine for patient management,
personal research and communication. Recently, the utilization of massively
parallel processing, brought about by distributed computing grids, has allowed
for cancer researchers to develop drugs and test therapies at speeds never
before available. The use of distributed computing in testing molecules for
their cancer protein binding potential, automated tissue microarray analysis and
tumour growth modeling are all currently promising research areas. Despite
some inherent challenges, distributed computing may one day be used
extensively in all areas of medical research.
This article has been reviewed by Dr. Eric Wong and by Dr. Wayne Weston and by Dr. Victor Han.
The Internet may be synonymous with browsing and email, but its utility is much greater. The
Internet is often used to garner information, be it a patient searching for facts regarding a recent diagnosis,
or a physician trying to find the latest published research on treatment for an obscure disease. A conceptual
link which is not immediately made, however, is the applicability of computers and the Internet in
producing potential breakthroughs in cancer research.
Cancer research has traditionally focused on exploring epidemiology, practical experiments in
molecular biology, clinical trials of potential medications or therapies and, more recently, an exploration of
immunotherapy and gene therapy. It is a direct extension of cancer research’s foray into molecular biology
and genetics which has ushered in the use of computers in the oncological arena.
History of distributed computing
Since the birth of computers over fifty years ago, the raw speed of computation has increased by a
factor of over one million.1 Despite this increase in computational power, personal computers are still
considered extremely slow in terms of requirements for solving highly complex scientific problems. 1
Cancer research is one such area where the complexity of molecular and biological interactions practically
precludes the use of even modern personal computers in any but the simplest experiments.
One method of solving this problem emerged in the 1980’s, and involved clustering multiple
individual computers to form what was termed a ‘supercomputer’.1 While these combined computers have
powers greatly exceeding those of individual units, the supercomputer must remain in a dedicated location,
and both physical and economical constraints limit the system’s size.1 This static model of a supercomputer
eventually evolved with the proliferation of the personal computer to ordinary individuals. With the
subsequent advent of the Internet, a means of connecting individual computers located thousands of
kilometers apart was feasible, and the birth of ‘distributed computing’ or ‘GRID computing’, was made.
Before long, it was realized that most of the current 400 million computers’ processors sit idle for long
periods of time, thus providing a potentially enormous computational resource. With the use of distributed
computing, the formation of a supercomputer consisting of thousands or millions of individual computers
was possible and finally ushered the way towards truly useful cancer research using computers.
Current implementations of distributed computing projects involve both a central server and client
software downloaded by individual users.2 A simplified explanation of the system revolves around the
server breaking apart a complex project and distributing chunks to individual clients. The client computers
process these chunks, during idle processor time or when a screensaver is running, and the forward the
completed work to the central server. The server combines these with other completed chunks and
distributes further work to the clients.3
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While many scientific projects attempted to make use of distributed computing, cancer researchers
quickly discovered the value this system could have in solving some previously insurmountable molecular
biology problems.
Searching for anti-cancer drugs
One project, funded by the National foundation for Cancer Research and run by Oxford University
and United Devices, aims to discover drugs suitable for killing cancerous cells or retarding their growth.
Normally, it takes between 12-15 years from a molecule’s discovery to go through the process of
effectiveness and safety testing and regulatory approval to finally reach the consumer market. Almost half
this time is spent screening potentially therapeutic compounds, a time which this project hopes to reduce
significantly.4
In essence, the Cancer Project engages in a game of reduction and simplification. The project
started with a list of over 1 billion compounds found in commercial catalogues and combinatorial chemical
libraries. The list was reduced to compounds with drug-like properties, namely ones with suitable
molecular masses and solubilities, which yielded a total of 35 million compounds. With this list, an
exchange of various functional groups in each molecule produced 100 derivatives for each compound,
producing a final collection of 3.5 billion potential anti-cancer drugs.4 Twelve cancer-related proteins, with
established active sites, were subsequently chosen for testing. Each of the 3.5 billion compound was to be
tested against these active sites, in order to discover which would bind and potentially interfere with the
given cancer protein’s method of action.4
Even with the small list of proteins being investigated, the vast number of potential molecules and
bindings was daunting. Moreover, in order to reduce error and improve quality and reliability, each
molecule needed to be tested multiple times and ranked in terms of binding potential and binding energies.
The sheer scale of the projected evolved into the largest computational chemistry project ever undertaken.5
One year after the project’s launch however, over 1.5 million volunteer computers were recruited, in over
200 countries, producing a virtual supercomputer which had processed over 100,000 years worth of CPU
time.4 Calculations were proceeding at a rate of 15,000 molecules screened every second and eventually
came up with a list of 800,000 potential molecules in 2002.5
While this ‘shortlist’ of molecules is only a fraction of the original 3.5 billion, it is still far from
being a feasible amount testable against cancer. The project has since continued to a second phase, where
distributed computing, together with software called LigandFit, will determine, and more accurately
prioritize, the suitability of these molecules for actual drug development. As of this year, the second phase
of the project has involved over 1.9 million volunteers and has computed almost 43 years worth of
computational time, but is not yet complete.5
While this project’s progress seems highly encouraging, there are still many difficulties in the
approach. First, the active site on target proteins may not always be previously known. While brute-force
computational searches for binding sites based on ligand-protein energy of interaction can be attempted,
this is not feasible. The amount of calculations necessary for this type of search far outnumbers the
capabilities of even the largest of distributed computing systems.5 An efficient automated method of
discovering these active sites must be developed, or else searches must be limited to small parts of the
molecule instead of complete ligands. A second problem does not involve computation power, but rather
social aspects of the system. As distributed computing requires large amount of volunteer computers, a
given computational power cannot be guaranteed. Individuals may lose interest and uninstall the program
or competing research may foster greater support and thus eliminate potential participants from the
available pool. Furthermore, questions of security and viruses, of paramount importance to today’s
consumers, must be addressed before widespread acceptance is achievable. There are methods of
combating these risks, but they must be used effectively and transparently to the end-user. Efforts at
recruitment, either through appropriate advertisement or incentives, must be considered if distributed
computing is to be used successfully for future projects. Also, this type of investigation is hypothesis
generating and not hypothesis testing in nature. Thus, while research such as the Cancer Project may
eventually narrow down a small list of drugs to be tested, drug company involvement, governmental
regulation and most importantly, in vivo testing, must all be completed before successful drugs can be
produced and used.
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Other distributed computing cancer projects
Distributed computing, in its fight against cancer, is not simply limited to screening potential
drugs. A novel use of this technology is being developed utilizing IBM’s World Community Grid (a
distributed computing environment) together with a new tool called tissue microarrays (TMA). TMA’s
allow researchers to determine the specific cancer type and stage of a given tissue sample and
systematically determine which therapies may be effective. A specific treatment can then be utilized based
on the presence of a given biomarker. While TMA’s are arguably quite useful, their major limitation
revolves around the subjective interpretation of the array by observers.6 By digitizing the specimens,
computers can be utilized for this assessment, although the analysis is computationally very complex.
While few biomarkers have been examined to date, a large database of these markers, coupled with the
power of a distributed system, could allow parallel analysis of hundreds of arrays together with
simultaneous experiments on them. This increased speed in computation and analysis, which would not be
possible on an individual computer, could allow for the discovery of minute changes in measurable factors
and thus facilitate future research in cancer biology and drug discovery.7
Other cancer-related research projects utilize distributed computing in various ways. Some, like
Parabon’s Compute-against-Cancer, aim to analyze patient responses to chemotherapy and thereby mitigate
potentially adverse effects.1 Others, like Integrative Biology (IB), started in 2004, aim to develop allencompassing models for future research. IB is a project aiming to build a secure and resilient distributed
infrastructure which will be used to develop complex models of cancerous tumour growth. Eventually, it is
hoped this system will allow for the understanding of cancer’s biological mechanisms completely. This
system will utilize high-performance computers, large databases and complex visualization systems to
achieve this goal.8 While the technical methods of distributed computation are similar to those used in the
Cancer Project, the computer network consists solely of researchers and super-computers at specific
facilities, not necessarily volunteer computational cycles provided by individuals.
It is evident that distributed, or GRID, computing holds tremendous potential in the field of cancer
research. It is important to note that this technology is not limited to oncology, and has prospective use in
helping develop cures for many diseases ranging from AIDS, to Alzheimer’s. The ever-increasing speed of
both personal computers and the Internet will undoubtedly benefit future research utilizing this technology
and may, one day, make distributed computing a method of choice in developing better therapy for a wide
variety of diseases.
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History of Medicine
From Trephining to Genotyping: A brief look at the history of Neuro-oncology
Raza Naqvi, Meds 2009
Adam Garber, Meds 2010
The field of neuro-oncology has shown dramatic advancements over the past
several years after a period of relative quiet throughout much of the late 20th
century. We are at a pivotal turning point in the field as genotyping and further
advances in the use of chemotherapy continue to push the borders of brain
tumour therapy. Thus, it seems fitting at this point in history to have a brief
look at the origins of neuro-oncology and the more recent developments that
are advancing the field at a rapid pace. This article takes its readers through a
tour of the origins of neurosurgery and then analyzes the more recent
multimodal approach to neuro-oncology to give some perspective and
appreciation of this rapidly evolving field.
This article has been reviewed by Dr. Chris Watling.
Introduction
Despite having developed tremendously over the past several centuries, the field of neurology is
one area in medicine that is continuing to show rapid growth in all facets even today. With improvements
in imaging and genetic analysis, neurology is growing by leaps and bounds, transforming a specialty that
was primarily diagnostic a few decades ago to one in which interventional procedures and curative
treatments are becoming increasingly common.1-3
Another field which has continued to improve, thanks in large part to the advent of radiotherapy
over the past century and rapid developments in the field of chemotherapy, is that of oncology. Cancer
research has plastered the pages of the lay press on a daily basis over the past decade and continues to make
headlines within the scientific community as one of the fastest evolving fields in medicine today.
The field of neuro-oncology, in contrast, had a period of quiet in the last two decades of the 20th
century as research and trials were unable to keep up with developments in other areas of medicine. The
last decade, however, has seen progress in this blossoming field with the publication of several landmark
trials. This article will place recent developments in a historical perspective, beginning with early
neurosurgical work and concluding with a look at where current cutting-edge research is leading us today.
The beginnings and development of neurosurgery
Pre-1850: From trephining to anesthetics
Some form of neurosurgery existed in ancient societies, as evidence of trephining can be traced
back over three thousand years to Ancient Egypt.4 However it was in 1573 that Giovanni Croce published
Chirurgiae, a book which has the first depictions of a neurosurgical operation taking place.5 It was not until
1846 when William Morton discovered the usefulness of sulphuric ether, the first modern anesthetic, on the
16th of October at Massachusetts General Hospital6, that the field of neurosurgery began to flourish.
1850-1900: Removing tumours
These developments caused a flurry of activity on the surgical front and it was in 1879 that
Scottish surgeon William Macewen described what is believed to be the first removal of a dural based
tumour.7 It was a few years later in 1884 when British physician Alexander Bennett diagnosed a cerebral
tumour in a patient of his and decided that surgical intervention would be the best approach. He asked
surgeon Richman Godlee to operate and it was Godlee who carefully removed the tumour from deep within
the cortex. The patient died soon after of infection but autopsy results indicated that this was perhaps one of
the first gliomas to have been successfully excised from a patient.8
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1900-1950: Cushing to the gamma-knife
Surgical developments continued gradually over the next several decades and it was in the early
1930s when Harvey Cushing, a Professor of Surgery at Harvard Medical School, reported a remarkable
decrease in the mortality of neurosurgical patients over the previous decade. After statistically analyzing
over two-thousand verified tumours, Cushing showed significant decreases in the mortality rates of
neurosurgery used to treat acoustic neuromas (25.0 to 4.4%), gliomas (30.9 to 11.1%), meningiomas (21.0
to 7.7%), and many other cerebral tumour subtypes.9 These advancements are simply one example of
Cushing’s many significant contributions to the field of neurosurgery in the first half of the 20th century.
The next major development in the field of neurosurgery was the development of stereotaxic
surgery by Ernest Spiegel in 1947 as he used a stereotaxic frame to accurately localize sites for the biopsy
and treatment of neurological lesions.10 In 1950, Lars Leskell developed Spiegel’s apparatus to create the
concept of stereotaxic radiosurgery using the ‘gamma knife’. Leskell thus became the first physician to be
able to deliver radiation in a focused manner to localizable tumours within the brain.11
Post-1950: Microsurgery and beyond
Neurosurgical developments continued over the next several years and it was in the late 1960s that
Gazi Yagarsil, proclaimed “Man of the Century 1950-1999” by the well-respected scientific journal
Neurosurgery, developed the concept of microsurgery.12 He developed the idea of performing surgery on
small and delicate tissues with the aid of an operating microscope. This advancement in the field was
unparalleled in its significance over the second half of the 20th century as it allowed surgeons to operate
much more efficiently on the very fine and delicate structures within the brain.
Thus, in just over a century since the advent of modern anesthetics and the beginnings of surgery
as we know it today, the field of neurosurgery developed significantly, allowing a safer and more precise
approach to brain tumour resection. Advances in the field have continued over the past several decades but
this serves as an introduction to the origins of the field of neuro-oncology as it is known today.
Beyond neurosurgery
The first step: Combining surgery and radiation therapy
In 1978 a landmark study by the Brain Tumor Study Group and the National Cancer Institute
(NCI) reported on a prospective, randomized-controlled study which analyzed the use of a
chemotherapeutic agent, 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU), and/or radiation therapy in surgical
patients who were found to have anaplastic glioma.13 The results of this pivotal trial provided clear
evidence for the benefit of radiotherapy as it prolonged survival from 14 to 36 weeks versus controls. The
addition of BCNU alone produced a statistically insignificant increase in survival and the use of adjuvant
BCNU to radiotherapy also yielded unimpressive results.13 This study paved the road for treatment over
the next quarter century as postoperative cranial radiation became standard treatment for patients with
malignant gliomas, but the use of chemotherapy remained on the sidelines for the time-being.
A side-step: Genotyping and brain tumours
It would be at the University of Western Ontario in London, Canada that the next major
development in neuro-oncology would occur, over 20 years after the last milestone. In research that began a
decade earlier, it was reported in 1998 that anaplastic oligodendrogliomas with coincident loss of
chromosome 1p and 19q had increased susceptibility to chemotherapeutic intervention.14 The results were
monumental and led to a flurry of activity within the neuro-oncological field in attempts to more carefully
delineate genetic factors predictive of treatment response or prognosis. The use of genotyping and other
forms of cutting-edge medical technology are thus serving an important role in the development and
progression of neuro-oncology.
The second step: Surgery and chemotherapy… the relationship begins
Almost 25 years after the landmark Brain Tumor Study Group and NCI trial implicated that
BCNU had a minimal role in the treatment for malignant glioma, the results a multinational randomized
placebo-controlled trial that used BCNU wafers (Gliadel wafers) to complement surgery were published in
April of 2003. The results indicated that the insertion of a small biodegradable polymer containing BCNU
into the resection cavity at the time of surgery for malignant glioma increased median survival from 11.4 to
13.1 months versus the placebo group.15 Although the results may seem insignificant to most, this was the
single largest increase in survival of malignant gliomas post-surgery in over 25 years.
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The third step: Surgery, chemotherapy, and radiation therapy – finally united
In March 2005, Stupp and colleagues published the results in a multicentre international
randomized-controlled trial addressing treatment of glioblastoma multiforme. In this study, patients were
randomized, following maximum possible surgical resection, to receive either radiation with concurrent
chemotherapy with Temozolomide followed by six cycles of adjuvant Temozolomide or radiation alone.
Median survival in the radiation plus Temozolomide group was 14.6 months compared with 12.1 months in
those receiving radiation alone. However the research made waves among the neuro-oncological
community as it also indicated that combined treatment with radiation plus temozolomide led to two-year
survival rates of 26.5% versus only 10.4% in those given radiation alone.16 This near tripling of 2-year
survival rates was absolutely unheard of in the field of neuro-oncology.
Along with the publication of the landmark temozolomide trial came evidence by Monika Hegi
that silencing of the DNA-repair gene O6-methylguanine-DNA methyltransferase (MGMT) is positively
correlated to a significant survival advantage in those with glioblastoma multiforme.17 This finding
illustrates the pivotal role that molecular analysis is playing in the advancement of brain tumour.
Future Directions: A rapidly evolving field
After nearly twenty years of largely unsuccessful efforts, the field of neuro-oncology has shown
considerable developments over the past decade. With continued advancements in the fields of radiology,
gene therapy, and cancer therapeutics in general, neuro-oncology has tremendous potential for development
over the coming years. We are thus clearly at a frontier in the treatment and management of brain tumours
and this brief look at past achievements in neuro-oncology provides perspective on future advancements.
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Health Promotion
HPV Vaccination
Jennifer Clara Tang, Meds 2009
Jonathan Klein, Meds 2010
“One less daughter, one less sister, one less friend… whose life might be
affected by cervical cancer. With Gardasil™, you could be one less.”1
The young hip-looking teenager speaks this phrase with deep conviction as she
stares out from the television. The North American approval of Gardasil™ , a
vaccine against the human papilloma virus (HPV) by Merck Frosst, has led to a
media surge. As of July 10, 2006, Health Canada issued market authorization
for sale and distribution of Gardasil™.2 The Society of Obstetricians and
Gynecologists of Canada (SOGC) has been actively increasing its promotion of
HPV awareness through radio spots and campus flyer distribution. Indeed,
thanks to increasing media attention, HPV is the “disease de jour” that medical
learners should understand. This review article hopes to provide a broad
overview of HPV including current vaccines, guidelines surrounding these
drugs, and challenges facing future vaccination programs.
This article has been reviewed by Dr. Osman Tarabain.
Background
In the past, HPV was overshadowed by other sexually transmitted infections like HIV, chlamydia,
and gonorrhea. Many patients are oblivious to the fact that HPV is the most commonly sexually transmitted
infection in the world. 3 There are over 96 different strains of HPV, 30-40 which infect the genital tract. 4
This group can be further subdivided into low risk HPV (which, at worst may cause ano-genital warts) and
high risk HPV (associated with cancer). Condoms provide little protection, as HPV is transmitted through
affected skin to skin contact. In most healthy individuals, HPV can be cleared by the immune system,
leaving the patient no indication that they ever contracted the virus. However, if left untreated, certain
strains of HPV, may lead to the second deadliest global cancer in women: cervical cancer. 5 Anal, vaginal,
vulvar and oral cancer may also result. Health Canada estimates that 75 percent of Canadians will have at
least one HPV infection in their lifetime. 6 A vaccine for HPV would hold great promise for developing
nations, as they carry 80% of worldwide cervical cancer incidence and mortality. 7
Mechanism of Infection
HPV is a double-stranded non-encapsulated DNA virus with an 8 kb circular genome. Its viral
capsid is formed by structural proteins L1 and L2, which play an important role in the vaccination. The
virus is introduced through erosion or microtrauma of the epithelial layers, then proceeding to infect basal
squamous epithelium. In a worst case scenario, a high risk strain of the virus will hijack basal
keratinocytes, amplify itself, and slowly cause dysplasia, carcinoma in situ and finally, invasive carcinoma
(fig 1). As mentioned previously, most patients affected with HPV will clear the infection. The time from
viral infection to noticeable cauliflower-like lesion on affected skin can range from weeks to months. The
time span from infection to development of invasive carcinoma, is roughly 10 years. This long time span
explains why the incidence of cervical cancer rises over age 25 and is highest for women over the age of 40
years5. Early identification of any dysplasia through the pap smears has helped to drastically reduce
mortality due to cervical cancer (reduction in incidence rates from 21.6 per 100,000 in 1969 to 10.4 per
100,000 in 1990). 8 Yet despite these screening efforts, every year cervical cancer continues to claim the
lives of 273,500 women worldwide. 9 An effective vaccination for HPV has the potential to eliminate
associated cancers.
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HPV Vaccination
Merck Frosst and Glaxosmithkline have both developed HPV vaccinations, (Gardasil™ and
Cervarix, respectively) though at the time of this publication, only Gardasil™ is available in Canada and
the USA. The current formulation of Cervarix only protects against HPV 16 and 18. Gardasil™ is a
quadrivalent vaccine derived from yeast cells which protects against the two most common high risk strains
of HPV (16 and 18, associated with 70% of cases of cervical cancer) as well as the low risk strains (HPV 6
and 11, associated with genital warts). 5 Gardasil™ requires 3 intramuscular injections of 0.5 mL; the
second dose is given 2 months after the first, and the third dose is given 6 months after the first. The
current cost of Gardasil™ is $135.00. 10 Currently it is available for women, ages 9-26 years, though
Merck advises inoculation prior to sexual debut. 11 It is not currently recommended for use in men or
women over age 26 years as not enough research has been performed in these groups. If administered to
women who already have HPV, it cannot alter the course of that strain, however, it will protect against the
other 3 strains. The vaccine does not protect against all oncogenic strains of HPV, thus women who are
vaccinated should continue to be screened with pap smear.
Both vaccinations work by exposing the body to subunits of selected strains of HPV in order to
elicit an immune response (production of serum antibodies). The L1 viral protein is the major component
of the vaccine; clinical trials have shown its ability to self assemble into virus-like particles that
successfully induce high levels of neutralizing antibodies in subjects. The vaccine would enable the body
to identify and eliminate certain strains of HPV before they have a chance to hijack epithelial cells and
cause cancer. Thus far, L1 viral proteins have demonstrated strain specificity (i.e. if vaccinated against
HPV 16 with its L1 VLP, the patient is only immune to this strain; they do not have cross immunity against
other strains of HPV).
Gardasil™ has proven to be very successful in reducing the incidence of a “cervical cancer”
endpoint as defined by the FDA Vaccines and Related Biologicals Advisory Committee. Since it would be
unethical to use cervical cancer as an endpoint to determine success of vaccines, the FDA designated
development of histologically determined CIN (cervical intraepithelial neoplasia) grade 2 or higher on pap
smear as a surrogate endpoint. 12 The original cohort of subjects inoculated with Gardasil™ (n= 468) has
been followed for 1.5 years; to date, the vaccine has been 100% effective in preventing CIN 2 or higher
associated with HPV 16 and 18, as well as any genital warts associated with HPV 6 or 1113. One major
limitation to Gardasil™ is unproven duration of immunity. 11 Studies looking at HPV 16 specific
vaccination have demonstrated efficacy at 3.5 years post inoculation, however, more research needs to be
done to establish duration. Gardasil™ has not been associated with any serious side effects, but as with
duration of immunity, more time must pass before it can be declared free of any serious long term effects.
Challenges
While the development of a vaccination for HPV holds tremendous potential, there are several
hurdles that stand in the way of worldwide distribution. Cost and ease of delivery are important issues,
especially when considering use of the vaccine in developing countries. The stigma associated with
vaccination for an exclusively sexually transmitted infection is another hurdle that must be overcome.
As mentioned previously, developing nations carry 80% of worldwide incidence of cervical
cancer. The HPV vaccine has the potential to save countless lives, yet when statistics indicate that 40% of
children from developing nations are not vaccinated for life-threatening diseases like measles, it is difficult
to imagine how an expensive and labour intensive (3 injections) vaccine like Gardasil™ might be
administered. 14 Identifying a cost-effective form of the HPV vaccine is one of the areas of research
supported by a $28 million dollar grant from the Bill and Melinda Gates Foundation. Possible HPV
vaccination programs are limited by temperature sensitive nature of the vaccine as well as the requirement
for multiple injections over 6 months. Research has been done to explore the option of a one-time
intranasal delivery of vaccine. 15 Future HPV vaccines must be inexpensive, easy to administer and require
little commitment from the patient. Although not as major a factor in developed countries, cost is still an
issue. At $135.00 for a course of three injections, the cost is prohibitive for some lower-income women.
Critics fear that the expense of the vaccine will turn HPV and cervical cancer into diseases of the poor.
Prince Edward Island is considering coverage of the HPV vaccine under its provincial health plan. 16 As of
January 2007, New Hampshire will be the first state to offer free HPV vaccine to girls aged 11 to 18 years.
17
From a purely economic standpoint, it is not clear that provincial funding of the HPV vaccine will
reduce overall costs associated with cervical cancer. The vaccine will not eliminate pap smears, as current
vaccines only guard against 2 strains of HPV and other strains might still cause cervical cancer.
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Stigma associated with vaccination against sexually transmitted infections is a problem faced in
both developing and developed nations. Some lobby groups fear that vaccination will encourage
promiscuity. Others fear that the vaccination may provide a false sense of security to the patient. Attitudes
of both the physician and the patient play a major role in the success of vaccine programs. An American
study of opinions of adolescents and adults found that “recommendation by physicians was one of the most
important factors that would most influence their decision to be vaccinated against HPV” 18. A Mexican
study reported that “perception of cervical cancer risk and knowledge of the benefits of the HPV vaccine
were the 2 important factors that mothers said would influence them to allow their teenage daughters to get
vaccinated”. 19 Not surprisingly, a study of American pediatricians found that good knowledge of HPV was
a primary factor influencing their likelihood of recommending the vaccination to adolescents in their
practice. 20 A survey by the SOGC indicated that 87% of Toronto, Ontario high school students had not
heard of HPV. 3 Public education through initiatives like the SOGC’s award winning sexual and
reproductive health website (www.sexualityandu.org) is essential to overcoming stigma. 21
Conclusion
The development of an HPV vaccine is an important step towards eradicating cervical cancer.
Further research needs to be done to clarify the following issues: i) duration of immunity provided by the
vaccine, ii) use of the vaccine in men and women older than 26 years, iii) cost of the vaccine and iv)
development of a single injection vaccine (as opposed to 3 separate injections). Both physicians and the
public should be educated about HPV so as to overcome stigma surrounding vaccination. There is great
optimism that in Canada, stigma over vaccination for HPV may not be an insurmountable obstacle. The
path has already been blazed with the introduction of the hepatitis B vaccination in the early 1990s. 22 Like
HPV, Hepatitis B is an oncogenic virus that is sexually transmitted. Today, vaccination for hepatitis B
takes place routinely in elementary schools nationwide. With continued efforts, school age HPV
vaccination may be routine in the next 10 years.
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Medicine and the Law
BRCA Genetic Testing: Ethical, Legal and Policy Considerations
Christian Fortin, Meds 2009
Michael Slatnik, Meds 2010
There is a concern that life insurance companies will use genetic tests to deny
coverage or charge increased premiums to patients with mutations for genetic
disorders. Those in favour of restricting an insurer’s ability to use genetic
information suggest that the fear of genetic discrimination will deter patients
from pursuing important genetic testing. Others argue that restriction will
disrupt the insurance industry because it will allow high-risk patients to
purchase life insurance policies at rates that underestimate the true risk of
mortality. This essay focuses on the BRCA genes and reviews the literature to
evaluate the possibility that (1) mutation positive individuals will purchase
additional insurance to the detriment of other insured individuals, or that (2)
women will avoid genetic testing and therefore forego the opportunity to
benefit from prophylactic therapies. The paper discusses the current state of the
law, possible policy directions, and the need for lawmakers and insurers to
develop appropriate measures before emerging genetic technologies can
calculate genetic risks with greater certainty.
This article has been reviewed by Dr. Lois Champion.
Introduction
One of the most important ethical debates of the Human Genome Project arises from the
possibility of ‘genetic discrimination’. Many people are concerned that one’s genetic status, as revealed by
genetic testing, could serve as a basis for wrongful discrimination relating to the provision of consumer
services. There is a particular concern that life insurers could charge increased premiums to those
predisposed to genetic disorders. It is controversial as to whether the use of genetic information by
insurance companies would be an acceptable business practice or conduct akin to racial discrimination.
The BRCA genes, which are more fully described below, are particularly relevant in evaluating
the potential role of genetic information in the insurance underwriting process as mutated BRCA genes
confer a calculable risk of breast and ovarian cancer in women. Moreover, prophylactic therapies are
available to affected women. The BRCA genes will thus serve as a model in the following discussion of the
ethical, legal, and policy considerations related to the use of genetic information by life insurers.
The BRCA genes
Breast-cancer associated genes 1 and 2 (BRCA1 and BRCA2) were discovered in 1994 after
extensive studies and molecular testing of women in hereditary breast and ovarian cancer (HBOC) families.
Both BRCA1 and BRCA2 are tumor-suppressor genes which, when mutated or defective, result in some
loss of cell-cycle regulation and a 50-80% risk for developing breast cancer, along with increased
susceptibility to ovarian cancer.1 The BRCA genetic test involves direct nucleotide sequencing of the
BRCA1 and BRCA2 genes and costs thousands of dollars in a US laboratory. Interventions available to
affected women include chemoprevention, and bilateral prophylactic mastectomy and oophorectomy.2
Evidence to guide policy direction
Policy relating to genetic testing should be guided by a thorough understanding of the tests and
their implications, as well as evidence regarding decisions pre- and post-testing. With genetic tests such as
BRCA, an issue relating to the business of life insurance is the information asymmetry that results after a
genetic test, resulting in the consumer having more information about their health if they choose not to
disclose their test results to a prospective insurer. The tendency of high-risk individuals to purchase
insurance at rates that underestimate risk is termed ‘adverse selection’ and is recognized as an undesirable
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consequence of restricting an insurer’s ability to utilize a prospective customer’s genetic test results.3
Insurance companies seek mandatory disclosure in order to accurately value insurance plans, whereas
genetic interest groups argue that mandatory disclosure results in discrimination and public reluctance to be
tested, and that voluntary disclosure is the best method.4
The decision to be tested for a BRCA mutation is one that has important repercussions and all
testing must be accompanied by proper genetic counseling. A study of women in a high prior-risk clinic in
Michigan showed that out of 184 candidates for testing, only 106 (58%) underwent testing and of those
who declined, 48/78 (62%) cited concerns about cost and insurance discrimination as the reasons for not
undergoing the test.5 This same study estimated that half of patients declining testing for insurance
concerns would be positive, and in high prior-risk clinics, approximately 25% of patients will decline
testing for reasons of cost, confidentiality and insurance concerns. Fear of genetic discrimination are
prevalent even in those highly educated in health policy; in a survey of the Special Interest Group in Cancer
of the National Society of Genetic Counselors (USA), 68% undergoing genetic testing would not attempt
reimbursement from their insurance company for the test for fear of later discrimination, and 26% claim
they would use an alias for the test.6 Policy must be in place to clarify confidentiality issues and the use of
genetic testing in insurance and healthcare settings in order to prevent public reluctance to be tested, which
would decrease the positive benefits of testing.
As described above, insurance companies fear that those with the informational advantage of
positive genetic tests will purchase additional policies, and cite this possibility of adverse selection as a
reason for mandatory disclosure of tests. In a one year follow-up of a group of Utah women who underwent
BRCA1 testing, it was found that consumers do not exploit the information asymmetry caused by genetic
testing: none of family history, testing status or participation in early BRCA1 research seemed to be
indicators of demand for life insurance, and the only factors found to influence insurance policy purchase
were socioeconomic ones.7 The women who tested positive were found to have statistically similar
amounts of life insurance in comparison to those who tested negative. Conversely, another study of women
undergoing BRCA testing or counseling revealed that the decision to increase life insurance coverage was
associated with a positive BRCA test.8 The paucity of empirical research, along with conflicting results of
studies described above, suggests that much more research is need to determine if restricting insurers’
ability to use genetic information for actuarial calculation will result in adverse selection.
The Concept of Genetic Discrimination
The precise meaning of discrimination is often confused in the context of risk calculation based on
genetic status in the life insurance industry. Insurers intentionally use the word ‘discrimination’ in the sense
of merely drawing distinctions among individuals based on generally accepted principles of actuarial
science. Discrimination utilized in this neutral sense must be distinguished from the kind of discrimination
that is deemed illegal and wrongful under human rights legislation. In Ontario, the Human Rights Code
prohibits discrimination relating to such areas as services, accommodation, and employment on a discreet
number of enumerated grounds including race, ethnic origin, sexual orientation and age.9 However, one
who discriminates on one of these or other enumerated grounds can often justify discriminatory behaviour
by demonstrating that a distinction was drawn on bona fide and reasonable grounds. The Supreme Court of
Canada has acknowledged that the calculation of insurance premiums does not fit easily with concepts of
human rights norms, but has justified the practice of differential treatment that is based on sound and
accepted underwriting procedures and if there are no practical alternatives.10
Some leading Canadian commentators on this topic suggest that discrimination on the basis of
genetic status, as revealed by a predictive genetic test, will be wrongful in the insurance industry only if
there is no actuarial basis for concluding that a customer is at increased risk.11 These critics often call
attention to the fact that family history—which often serves as a proxy for genetic risk—plays a valid role
in life insurance premium calculation. Other critics highlight the fact that some patients oppose the practice
of drawing distinctions on genetic status, even if genetic tests can accurately predict the risk of mortality. In
discussing BRCA predicting genetic testing, one scholar notes that “the public may believe differential
pricing based on breast cancer risk would be socially intolerable, even though actuarially fair.”8 It has been
noted that Canadian human rights law is evolving and might place restrictions on the ability of insurers to
use genetic information when calculating premiums.12 There is a good probability, however, that
differential premiums based on genetic status will be justified if based on sound scientific principles and in
the absence of alternatives.
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Policy Alternatives
Potential strategies at addressing the inevitable problems created by life insurers’ use of genetic
information include legislative prohibition, the establishment of moratoria upon insurers, and maintenance
of the status quo. Many European Countries including Austria, Belgium, and Denmark have embraced the
first option and have enacted legislation that places an outright restriction on a life insurer’s ability to
request or use genetic testing in calculating premiums.12 The Netherlands has adopted a similar approach
but only to policies below a predetermined monetary figure, thereby ensuring that all individuals can
purchase a basic amount of life insurance.11 Moratoria are usually established by the insurance industry but
often at the behest of governments. Insurers within the United Kingdom utilized the moratorium method in
the past, but reserved the right to use genetic information when approved by a governmental committee and
when the insurance contract was over a specified amount. The rationale of this moratorium was to give the
industry and the relevant authorities more time to converse and possibly develop a framework for the use of
genetic information in life insurance premium calculation.13 Finally, the status quo approach leaves it to the
life insurance industry to decide for itself how to use genetic information. Canada appears to have opted for
the status quo; there did not exist any provincial or federal legislation regulating life insurers’ use of
genetic information or a self-imposed industry moratorium during the preparation of this article.
In 2004, insurers, patient advocates, and researchers knowledgeable in genetics policy established
the Canadian Genetics and Life Insurance Task Force to suggest policy options relating to life insurance
and genetics.14 The task force urged policy-makers, insurers and physicians to debate the merits of either
(1) imposing a temporary moratorium on the use of genetic information for life insurance policies below a
specified amount, or (2) creating an independent standing body that would oversee the use of genetic
information by life insurers. It is not clear whether stakeholders took up this challenge.
Concluding Comments
Reports of actual discrimination on the basis of predictive genetic test results have hitherto been
scarce.15 Policy makers, therefore, have some time to debate the benefits and drawbacks of regulating a life
insurers’ ability to use a customer’s genetic status in their underwriting activities. On the other hand, the
number of diseases for which there are genetic tests increased 600% from 1997 to 2006.16 It is therefore
crucial to have policy directing the use of genetic testing which strikes an appropriate balance between
encouraging patients to access beneficial genetic testing and promoting a fair and effective life insurance
regime.
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Zebra Files
Microcystic Adnexal Carcinoma
Tiffany Kwok, Meds 2010
Badrinath Narayan, Meds 2009

Microcystic adnexal carcinoma (MAC) or sclerosing sweat duct carcinoma is a
rare slowly growing but locally aggressive malignant skin tumour displaying
sweat duct and pilar (follicular) differentiation. It typically occurs on the face
of middle aged adults. MAC is frequently misdiagnosed because of its
asymptomatic clinical presentation and bland histology on superficial small
punch or shave biopsy. Because of its deeply infiltrating nature, the optimal
biopsy for MAC is incisional or excisional biopsy. Lack of early diagnosis can
lead to an aggressive neoplasm with high rate of recurrence, and rarely regional
and distant metastasis. Micrographic Mohs surgery is the preferred treatment
of choice for MAC. A case history of a recent patient with MAC treated at
London Health Sciences Centre is reviewed.
This article has been reviewed by Dr. Mariamma Joseph and Dr. Dao Nguyen.
Introduction
First defined by Goldstein and colleagues in 1982, there have been only approximately 150 cases
of MAC described in the English medical literature.1 MAC is a slow-growing albeit locally aggressive
adnexal carcinoma with a high tendency to recur despite excision.1 Its aggressive nature is often due to
delay in diagnosis, inadequate tissue sampling and thus, detection at an advanced stage of disease with
invasion beyond skin into underlying tissue.1 Thus, a high index of suspicion is necessary in assessing
these tumours and adequate deep biopsy for diagnosis are essential. Surgical excision with clear margins
are crucial in prevention of local recurrence and distant metastasis. We review the clinicopathologic
features of MAC and present a recent aggressive case of MAC involving the scalp of a 58 year old woman.
Clinical Presentation
MAC typically presents as a slowly-growing flesh-coloured, yellow or erythematous firm plaque
or nodule in the head and neck region. Caucasians are affected most frequently and there does not appear to
be a gender predisposition. The tumour presents in a wide age group (11-90 years) although the majority of
those affected are between the ages of 40 and 60 years. The patient often presents with a lesion which has
been present for several years and has grown slowly.
At diagnosis, most tumours measure between 0.5 cm and 2.0 cm in diameter but occasionally can
be very large measuring up to 12 cm.3 The skin surface of MAC is usually smooth and non-ulcerated,
unlike other cutaneous carcinomas. It is almost always unilateral and predominantly left-sided in North
Americans2, a fact that has been suggestively attributed to greater sun exposure of the left side of North
American drivers.3 MAC has mostly been found on the cheek, lips, nasolabial fold and in the periorbital
area2,3,4 and is less common in the nose, scalp, eyelid and eyebrow.6,7 Typical clinical presentation of MAC
can be seen in Figure 1.
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Figure 1.
MAC, clinical. A small indurated
tumour is present on the upper lip. 13

1
Generally, the tumour is asymptomatic, until invasion into underlying tissue develops, causing symptoms
which may include pain, stinging, change in sensation or functional motor loss due to perineural invasion.3
Metastasis of MAC is rare, with only four described cases in the literature. One recent case described
MAC in the axilla metastasizing to the axillary lymph nodes.8 Haematogenous metastasis of MAC to liver
and bone with intracranial spread along optic nerve into the cranium has also been discovered on autopsy of
a 73 year old woman.3
Diagnosis
The diagnosis of MAC is made by full-thickness tissue biopsy. CT or MRI may be necessary for
tumour staging and treatment planning.1
Histologically, MAC is a poorly circumscribed deeply invasive tumour composed of variable
portions of keratocysts, basaloid or squamoid nests and infiltrating cords and ductular structures set in a
paucicellular desmoplastic stroma. Keratocysts are usually present in the superficial portion and cords of
cells and perineural invasion characterize the deepest portion, thus inadequate depth of tissue biopsy may
result in failure to diagnose this malignancy The nuclei of all these cells are rather uniform with only
minimal pleomorphism or atypia. Mitotic figures are very rare. MAC is mostly located in the dermis but
can infiltrate to subcutaneous fat, skeletal muscle, perichondrium, periosteum or perineurium. The
histology of a typical case of MAC is presented in Figures 2A-D.

2A
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Figure 2. MAC, histology. 2A) The dermis is widely infiltrated by tumour showing superficial
keratocysts (arrow) and deep narrow epithelial strands. 2B) Note the bland uniform cytology of
epithelial cells. 2C) Ductular differentiation is present (arrow). 2D) Perineural invasion is present
(Hematoxylin-Eosin stain).
Deep incisional or excisional biopsy would demonstrate deep infiltration of MAC and possible
perineural invasion allowing accurate diagnosis. A small superficial punch or shave biopsy that includes
only keratocysts and bland basaloid cells may lead to an erroneous benign diagnosis of syringoma or
trichoepithelioma. The area of the biopsy could also lead to an incorrect diagnosis of squamous cell
carcinoma if the sample contains high levels of keratinised cells with few tubules.2,7
Immunohistochemistry of MAC supports ductal differentiation, with positivity for Epithelial
Membrane Antigen (EMA) and Carcino Embryonic Antigen (CEA), features common to many adnexal
tumours with ductular differentiation.
Histogenesis
The histogenesis of MAC remains uncertain, but Goldstein considered origin from pleuripotential
adnexal epithelial cells capable of pilar (hair) and eccrine (sweat) gland differentiation. Mostly scientists
have postulated that MAC solely shows eccrine differentiation. Sub-clinical spread of the tumour beyond
clinical margins may be explained by invasion through shelving or conduit spread.1
Management and Outcome
The tumour does not generally respond to radiation treatment, and in those cases where response is
evident, there is a high rate of recurrence.2,6 Therefore, surgical excision is currently the best method of
treatment. Because of the tumour’s infiltrative nature, planned surgical excision margins are designed
widely, beyond the clinically evident margins of the tumour. Surgical treatment options for MAC include
wide local excision and micrographic Mohs surgery (MMS). MMS is currently the most widely accepted
surgical treatment. Although there are only few studies in the literature comparing the recurrence rates in
lesions treated with wide excision versus MMS, it appears that MMS provides the least morbidity and the
best chance for cure. The reported rates of recurrence with wide local excision are 40-60%.2,3 The
technique of MMS allows complete histologic examination of 100% of all margins while sparing maximal
amount of tissue6,10 in comparison to standard “bread-loafing” techniques which permit examination of
only 1-2% of specimen margins. The recurrence rate following MMS ranges from 0% to 12%.2,3,4 The
prognosis is good if local recurrence can be prevented. Only 1 case of death due to MAC metastasis has
been reported.1
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Case Report
A 58-year-old woman presented with a large pruritic hairless growth on the left side of her scalp
which had been present for over a decade and had previously been punch biopsied twice with diagnosis of
benign alopecia. She gave a recent history of paralysis of left side of face with drooping of left upper eyelid
and eyebrow and ulceration of the lesion. On examination, she had a large firm, indurated skin tumour (9.5
x 5.5 cm) with irregular borders surrounded by alopecia involving the left parietal region of the scalp
(Figure 3). A large elliptical skin biopsy confirmed the diagnosis of MAC. A CT scan of the head revealed
invasion of the tumour through the skull into the underlying dura and leptomeninges.

Figure 3.
MAC, clinical case. A large
indurated firm lesion with
irregular borders and focal
ulceration is present on the
scalp. There is surrounding
alopecia.

3
The tumour was widely excised by a plastic surgeon using a modified Mohs procedure with negative
circumferential peripheral skin margins, confirmed by frozen section examination intraoperatively. Classic
MMS technique was not feasible in this case due to the substantial size, location and infiltrative nature of
the tumour. The resected specimen included full-thickness scalp and portions of the skull and dura.
Pathologic examination showed classic features of MAC (Figure 2A-D). The skin and bone margins were
found to be clear on permanent section, and the patient subsequently underwent reconstruction of her
cranial defect. Adjuvant radiotherapy was instituted, however, aggressive local tumour recurrence
developed with brain metastasis. The patient expired 18 months following diagnosis.
Conclusion
Although rare, a high index of suspicion for MAC should maintained in the differential diagnosis
of slow-growing tumours in the head and neck region, particularly on the face. Prompt diagnosis and
treatment are crucial to prevent local recurrence and distant metastasis. Our case demonstrates a very rare,
aggressive form of MAC of scalp with invasion into bone and meninges, leading to brain metastasis and
death despite attempted wide surgical resection and radiotherapy.
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Feature Article
A Look at Acute Lymphoblastic Leukemia in Children
Wendy Ng, Meds 2009
Acute lymphoblastic leukemia (ALL) is the most common malignancy found
in the pediatric population. This type of cancer occurs in children in 2/3 of
cases, with a current cure rate of almost 80% in children. In comparison, only
30 to 40 percent of adults with ALL are cured, likely due to the higher
association of infavourable genetic abnormalities in adults’ leukemic
lymphoblasts.1 Usually occurring at approximately 2 to 9 years of age (Sather),
ALL presents with fever, fatigue, pallor and pain. At least half of patients with
ALL present with fever, often induced by pyrogenic cytokines released from
leukemic cells or due to infection.1 In contrast, acute myeloid leukemia (AML)
is less common than ALL, with an unclear etiology and similar presentation. A
discussion of the diagnosis, treatment and outcomes for ALL is presented, with
a particular emphasis on childhood ALL.
This article has been reviewed by Dr. Sam Yoshida.
Introduction, Characterization and Diagnosis
ALL can result from the blockage of any lymphoid cell at a point of development, and a diagnosis
of ALL is dependent on immunophenotyping.1 The diagnosis of ALL can be obtained by a bone marrow
aspiration.
The French-American-British (FAB) classification is based on morphology and simple
cytochemical stains. There are three major subgroups. By this system, FAB L1 is the most common, with
small cells, small nucleoli, and little cytoplasm. FAB L2 includes large cells, a clefted nucleus, large
nucleoli, and abundant cytoplasm. FAB L3 includes large cells, a homogenous nucleus, many nucleoli,
abundant cytoplasm, and prominent vacuoles. This system is effective, although cytogenetics and
immunophenotyping have been suggested to add further to diagnostic accuracy in some cases.2
Immunoflow cytometry determines the B cell expression of CD19 or CD 10 or cALLa
(common/childhood ALL antigen), a historical marker that is obsolete. TdT (terminal deoxynucleotidyl
transferase) is a marker for B cell leukemia, as well, but has been suggested to have both a low sensitivity
and specificity for prediction of relapse.3 T cell markers such as CD7, CD2, CD4 and CD8 can assist in
determining different treatments and survivals. On the basis of such immunophenotypic analyses alone,
firm diagnoses can be made in virtually all cases.1
Cytogenetic analyses look for hyperdiploidy and translocations. Patients with hyperdiploidy with
more than 50 chromosomes often have other clinical features that suggest a good prognosis.4 B cell
translocations include t(4,11)4, t(9,22)4, t(8,14)4, and t(1,19)6 which give poor prognoses. In contrast,
patients with t(12,21) generally have a favourable prognosis.7
T cell translocations, for example, include t(11,14).8 These patients are often young males, often
with associated unfavourable clinical characteristics. In addition, children with Philadelphia chromosomepositive ALL have been found to have a poor prognosis, with no consensus on the best treatment for this
variant.9
Associated Clinical Features, Treatments and Outcomes
The primary goal of therapy is to induce complete remission and to restore normal haematopoiesis.
Therapy for ALL is based on risk, wherein factors such as age, white blood cell count, patient gender and
cytogenetics must be accounted for.10,11 The presence of a mediastinal mass or central nervous system
leukemia also predicts a relatively poor prognosis.11 The inclusion of race or ethnicity as a part of raceadapted therapy, thereby allocating black and Hispanic children to more aggressive protocols, remains
debatable.12 Differences in clinically determined prognostic indicators are likely a result of the presence or
absence of genetic abnormalities.1
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Patients between the ages of 2 to 9 years with a white blood count of less than 50,000 microL are
considered to be at standard risk, with a high 4-year event-free survival of 80%.13 In turn, patients greater
than 10 years of age with a white blood count of greater than 50,000 microL are considered to be at high
risk, with a 4-year event-free survival of approximately 65%.13 However, patients at less than 1 year of age
with a white blood count of over 100,000 microL and with associated poor cytogenetics – such as the
unfavourable MLL translocations – are at very high risk.14 These patients have a reported survival of up to
50% with a sibling-donated bone marrow transplant and less than 30% survival with a matched unrelated
donor. With such a poor prognosis, infants with ALL are treated with multiple drugs at high dosages and
with no cranial irradiation.
As therapy for ALL improves, reported survival rates have increased over the years – with a cure
rate from less than 30% overall to 80% overall since 1970.15 Most standard risk and high-risk patients
should receive chemotherapy alone. Intensive chemotherapy includes fractionated high-dose
cyclophosphamide, high-dose methotrexate and cytarabine.1
Furthermore, male patients require a longer duration of therapy compared to female patients, as a
result of sanctuary sites. It has been reported that female patients have a better event free survival period
even when treated with less therapy.14 High risk patients with sanctuary site involvement, such as in the
central nervous system or testicles, should also receive radiation. However, since cranial irradiation can
result in significant neurotoxicity and predisposes to a risk of brain tumours, as well as to
neuropsychological deficits and endocrinopathy leading to short stature, obesity, precocious puberty and
osteoporosis, many physicians choose to administer intensive systemic chemotherapy early on, and
ultimately give patients growth hormone therapy to avoid negative endocrine-related effects.1 In addition,
high risk patients receive chemotherapy and consideration for bone marrow transplants. Flow cytometry
can be used as a prognostic indicator, as children with ALL who achieve a profound clearance of leukemic
cells after 2 to 3 weeks of remission-induction chemotherapy have been reported to have excellent
outcomes.16 It is an important challenge to integrate new data in the literature with modern methods of
assigning risk-based therapy.15 In addition, infections are a serious and common complication of therapy,
leading to death in many cases.14
Supportive care for patients with ALL includes the administration of broad-spectrum antibiotic
therapy for patients presenting with fever. At most centres, patients are treated prophylactically for
Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole at 3 days per week. Since
hyperuricemia, hyperkalemia and hyperphosphatemia with secondary hypocalcemia are common in
patients with a great burden of leukemic cells, patients should also be hydrated intravenously and treated
for these associated conditions.1
It should be noted that the third most common malignancy in children is relapsed ALL. For these
patients, therapy remains controversial, with debates over the benefits and risks of chemotherapy alone,
sibling bone marrow transplants, matched unrelated donor bone marrow transplants, with respect to the
optimal timing of bone marrow transplants, and the suggestion of no therapy at all. Conventional intensive
chemotherapy can cure up to 30% of children who have relapsed, and similar results have been reported
with autologous bone marrow transplantation.17
Conclusion
ALL is a serious disease, often occurring in children, and should be treated according to risk
stratification. However, despite major improvements in risk-assignment in recent decades, unknown
mechanisms still account for the successes and failures of therapy in individual patients. Efforts are
underway to identify new drugs and therapeutic approaches which may lead to options that are more
specific and less toxic compared to standard chemotherapy. It is promising to note that in the past few
decades, remarkable advances have been made in the cure rates of childhood ALL, and novel strategies of
treatment may ultimately result in better treatment options.
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Feature Article
Methods of Vascular Control in Liver Resection: A Review
Anton Cherney, Meds 2007
W. Davies, Department of General Surgery, UWO
Liver resections have historically been associated with high morbidity and
considerable mortality, directly linked to excessive hemorrhaging. To this day,
control of blood loss remains one of the key challenges in liver surgery. A
number of approaches can be applied to successfully reduce blood loss. These
include selective vascular control (SVC), continuous and intermittent portal
triad clamping (PTC), hepatic vascular exclusion with preservation of caval
flow (HVEPCF), and total hepatic vascular exclusion (THVE). For resection of
peripheral small lesions SVC is preferable since ischemic insult to the remnant
of liver is minimized. For more extensive lesions SVC results in unacceptable
bleeding and open approach with continuous or intermittent PTC is preferred.
Continuous PTC is associated with lower blood loss; with intermittent PTC
longer ischemic time is tolerated. Prolonged resections of massive tumors may
be best approached by HVEPCF with continuous or intermittent occlusion of
hepatic venous drainage. An alternative approach uses inflow occlusion with
occlusion of hepatic vein draining the segments being resected. Finally, tumors
invading hepatic veins or IVC are best approached using THVE, which allows
resection of venous confluence with adequate margins. The drawbacks include
significant hemodynamic disturbance and portal hypertension with bowel
engorgement. Increasingly complex and extensive hepatic resections
necessitate increasingly aggressive methods of vascular control. Under
appropriate circumstances each of these methods has a role in liver resections.
Selective Vascular Clamping (SVC)
The ligation of vascular pedicle to the segment of the liver being resected is the only method that
avoids ischemia and reperfusion injury to the remnant of the liver, which can decrease its ability to
hypertrophy and compensate postoperatively. Furthermore, SVC allows a clear demarcation of the
boundary between the hepatic segments with intact and disrupted blood supply. Portal hypertension, a
major drawback of PTC, is avoided or significantly reduced. The main concern with SVC is the potential
for profuse hemorrhage from the cut liver surface. Nonetheless good results have been reported, making
SVC an alternative to be considered.4 A randomized controlled trial by Figueras et al compared standard
PTC to SVC in liver resections involving two or less liver segments, finding no significant differences in
intraoperative blood loss.5 Wu et al describe several limitations of the hemihepatic SVC: additional 20 to
30 min are required for dissection of hepatic hilum, the technique is not suitable when the malignant tumor
invades the hilar plate, and in patients with dense adhesions of the hilum secondary to previous hepatic
artery embolization clamping may be especially challenging.6 Gotoh et al compare selective ligation of
vascular pedicles after intraparenchymal dissection to hilar lobar clamping and to PTC in patients with
cirrhosis and hepatocellular carcinoma. The lobar clamping group was found to have significantly shorter
operation time and intraoperative blood loss than the other two groups. On the basis of these results Gotoh
recommended lobar clamping as a method of vascular control, especially in cirrhotics.7 These results show
that under appropriate circumstances SVC can be used with low risk of excessive hemorrhage, while
ischemic injury to the liver is minimized. The role of SVC remains mainly in minor liver resections of
peripheral lesions, where severe hemorrhage is less likely to occur.
Portal Triad Clamping (PTC)
Hepatic inflow occlusion is simple to perform, involving placement of a vascular clamp over the
hepatoduodenal ligament. Care must be taken to identify the presence of any accessory hepatic arteries and
the numerous collaterals present in cirrhotics. In the only randomized controlled trial to demonstrate

UWOMJ 76(1) 2007

- 39 -

effectiveness of PTC in controlling blood loss, Man et al report that PTC was associated with lower blood
loss per resection area, shorter operative times, and improved postoperative liver function compared to liver
resections without extrahepatic vascular control.4 Overall PTC is well tolerated: liver with unimpaired
parenchyma can be safely exposed up to 60 min of normothermic ischemia.8 If longer time is required, PTC
can be used intermittently with 15-20 min ischemic intervals separated by 5 min reperfusion intervals. The
hemodynamic disturbance during PTC is tolerated by most patients.9 However, PTC allows backbleeding
from the hepatic veins that can contribute to blood loss. A common way to minimize this involves using
low central venous pressure (CVP) anesthesia; this is accomplished with restriction of IV fluids and, if
necessary, infusion of intravenous nitroglycerin.10 The danger of low CVP is the increased possibility of
potentially lethal air embolism during resection. Another drawback of PTC is portal hypertension and
venous stasis. King et al report significant ischemic changes in the bowel following 60 min of PTC.11
Finally, since PTC alone does not control the hepatic veins, in resections of tumors encroaching on the
hepatic venous confluence or directly involving intrahepatic vascular structures more extensive methods of
vascular control are preferred.

Figure 1. The Pringle maneuver,
or portal triad clamping (PTC):
portal triad is isolated and
controlled with umbilical tape or
vascular clamp.

Hepatic Vascular Exclusion with Preservation of Caval Flow (HVEPCF)
Historically, retrohepatic control of hepatic veins was considered dangerous because of the
possibility of massive hemorrhage and air embolism with injury to these vital structures. If control of
hepatic veins could be established, it offers several key advantages. Surgery can be done in a bloodless
field, the danger of air embolism is eliminated, and preservation of caval flow avoids significant
hemodynamic disturbance of THVE. The technique of intermittent vascular exclusion can be applied,
extending the total ischemic time if needed.12-15 The dissection, however, requires difficult exposure and is
technically challenging. Smyrniotis et al compare hepatectomy with THVE or HVEPCF, and report that the
THVE group required more intravenous fluids and blood and demonstrated greater postoperative hepatic,
pancreatic, and renal function impairment. There was no difference in intra-operative blood loss.15
Comparing PTC to HVEPCF revealed that HVEPCF group was found to have significantly lower blood
loss, lower transfusion requirements, and shorter hospital stay than PTC group. On the other hand, the
incidence of postoperative complications was similar between the two groups and the postoperative
bleeding rate was higher in the HVEPCF group. Another approach is to clamp only the hepatic vein
draining the segments being resected. This reduces the length and complexity of dissection, while providing
very good control of hepatic venous blood loss. With these advances, many surgeons use HVEPCF as the
preferred method of vascular control in major liver resections.
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Total Hepatic Vascular Exclusion (THVE)
Total exclusion of the liver from the circulation involves applying clamps to hepatoduodenal
ligament, infrahepatic IVC, and suprahepatic IVC. The main advantages of THVE are operating in
bloodless field and prevention of air embolism with injury to hepatic veins. It is particularly valuable in
resection of tumors that lie in close proximity to major hepatic veins and where resection is technically
challenging. A major drawback of IVC occlusion in THVE is the severe hemodynamic disturbance
associated with a drop in preload and increase in total peripheral resistance.13, 16 Most patients can tolerate
these changes without hemodynamic instability, provided aggressive infusion of intravenous fluids is used.
Between 20% and 30% cannot tolerate the instability.14 A trial of IVC clamping of 3 to 5 minutes is usually
undertaken to assess the change in hemodynamic parameters. The length of ischemia that could be safely
tolerated during THVE is proven to exceed 60 min, and can probably be safely extended to 150 min.17
However, the advantages of THVE over PTC have been controversial. A randomized controlled trial, by
Belghiti et al, compared patients undergoing major liver resections using PTC or THVE and found no
significant differences in intraoperative blood losses or postoperative liver enzymes.18 Other major
downside of THVE is associated portal hypertension with bowel edema, exacerbated by disruption of
portosystemic shunts with occlusion of IVC. The ischemic time limit of THVE cannot be overcome by
intermittent clamping, which results in unacceptable hemodynamic instability. Blood loss with THVE is
minimized during the actual resection, but can be profound after the unclamping.17, 19 Potential causes of
technical failure with THVE include incomplete clamping, unrecognized anomalous origin of left hepatic
artery, or unrecognized venous inflow into excluded segment of the IVC from right adrenal vein or other
sources. If the exclusion is not complete, profound hemorrhage can ensue, with blood unable to drain to the
heart filling the liver towards the surgical field.

Figure 2. Total hepatic vascular
exclusion with cross clamping
suprahepatic IVC, infrahepatic
IVC, and portal triad clamping

To this day, control of blood loss remains one of the key challenges in liver surgery. A number of
approaches can be applied to successfully reduce blood loss and transfusion requirements. These include
selective vascular clamping, portal triad clamping, hepatic vascular exclusion with preservation of caval
flow, and total hepatic vascular exclusion. Each method has its downsides and offers its unique advantages.
For resection of peripheral small lesions SVC is preferable since ischemic insult to the remnant of liver is
minimized and danger of profuse hemorrhage is low. For more extensive lesions SVC results in
unacceptable bleeding and open approach with continuous or intermittent PTC is preferred. Prolonged
resections of massive tumors may be best approached by HVEPCF with continuous or intermittent
occlusion of hepatic venous drainage. Finally, tumors invading hepatic veins or IVC are best approached
using THVE, which results in significant hemodynamic disturbance and potential ischemic injury, but
allows resection of venous confluence with adequate margins. Thus increasingly complex and extensive
hepatic resections necessitate increasingly aggressive methods of vascular control.
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Feature Article
An overview of the screening and staging strategies for organ confined prostate
cancer
David Horovitz, Meds 2009
Prostate cancer is the second most common cause of cancer death and the most
frequently diagnosed cancer in North American men. Its behaviour is quite
variable, ranging from microscopic, well differentiated and clinically
unimportant to highly aggressive with extensive invasive and metastatic
capability. Disease that is confined to the organ is usually curable, but capsule
penetration, invasion of seminal vesicles, and metastases to lymph nodes
usually precludes this aspiration; hence, the widely held believe that much
effort should be directed at its early detection. Historically, this goal was met
via digital rectal examination and enquiries of urinary symptoms. However,
most PC diagnoses today are first discerned from elevated PSA levels, and
thus, most present asymptomatically. Many advances have been made with
regards to approaching this disease, and herein, an overview of the screening
strategies used to detect PC and subsequent diagnostic and staging methods
will be presented.
This paper has been reviewed by Dr. Glenn Bauman.
Prostate-specific antigen (PSA) is now routinely used as a prostate specific marker for the
screening of prostate cancer (PC) and plays a major role in diagnosing the disease. After all, many studies
have demonstrated that the likelihood of finding PC on biopsy increases with PSA levels, especially in
higher ranges, and various others have demonstrated that the use of PSA detects PC and raises its
incidence.
However, the viability of PC screening has been the focus of much controversy in recent years and
the Laval University Prostate Cancer Screening Program (LUPCSP) conducted the first prospective,
randomized trial in 1988 to try to resolve this issue.1 Here, 46, 486 men aged 45-80 were randomized into
either the screening (digital rectal exam (DRE) on first visit plus PSA measurements with 3.0 ng/ml being
the upper limit of normal) or control group, and after 11 years of follow up, 10/7348 and 74/14231 deaths
occurred in the two groups respectively, yielding a 62% reduction in cause-specific mortality.
The results of two larger international prospective RCTs are eagerly awaited by the oncologic
community: the Prostate, Lung, Colorectum and Ovary (PLCO) Screening Trial and the European
Randomized Screening Trial for Prostate Cancer (ERSPC). These were both established around 1994 and
the final evaluation may take another 10 years.2
Although the traditional cut-off for biopsy indication has been ≥4 ng/ml, the usefulness of this
value has come into question by recent studies stemming from the Prostate Cancer Prevention Trial
(PCPT).3 Here, 5754 men over the age of 55 were biopsied based on an indication of PSA ≥4 ng/ml or an
abnormal digital rectal examination (DRE). These parameters only resulted in a 24.7% detection rate.
Another group has demonstrated that as many 15% of men with PSA <4 ng/ml have PC and 15% of these
are high grade.4 These same authors have since reported the receiver operating characteristic curve for PSA
and have shown that there is no cut-off for healthy men that has both high sensitivity and specificity, but
rather a continuum of PC risk at all values of PSA.5
While it is generally accepted that the positive predictive value (PPV) of DRE increases with PSA
levels, its usefulness at low PSA values remains another topic of much debate. For instance, while
Carvalhal et al. concluded that “appreciable” PPVs for DREs could be obtained with low PSA levels,
Schroder et al found that they were “poor” in a similar European study and thus recommended that under
these circumstances, it should be replaced with a test of higher sensitivity.6,7
Different molecular forms of PSA are evident in serum and this may be helpful in differentiating
PC from benign prostatic hyperplasia (BPH), a condition that affects 25% of men above the age of 50.
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While 10-30% of total PSA is not bound to any other serum proteins, approximately 70-90% of the total
PSA is bound to α1-antichymotrypsin (a small amount is complexed with α1-antitrypsin, Protein C, and
α1-macroglobulin). Several studies have demonstrated that patients with PC have a lower serum ratio of
free PSA to total PSA than patients with BPH, and thus, fractionated PSA is an indicator that may allow for
differentiation.8
Suspicious screening results are usually followed up with a transrectal ultrasound (TRUS). Most
lesions are hypoechoic and are frequently best seen when small. In a series of 960 patients, it was found
that approximately 66% of cancers were hypoechoic while only 51% of these were actually cancer.9 Some
cancers may show areas of increased echogenicity, probably as a result of dystrophic calcification. While
25% of carcinomas may be isoechoic and therefore not visible on gray scale sonography, they may be
picked up on random biopsy. Colour Doppler may have a role to play in visualizing such tumours, but
there is incongruity in the evidence.10
Transcapsular invasion into the periprostatic fat may be difficult to detect with TRUS, especially if
it is subtle. The sonographic signs range from obvious tissue invasion to bulging of the gland with slight
compression. Involvement of the seminal vesicles may be seen as asymmetry in their shape, size, or
sonographic characteristics. Detecting cancer spread through the apex is also very difficult to do with
TRUS, and this is worrisome because a positive finding changes the treatment. Thus, in order to determine
the likelihood of either seminal vesicle involvement or extracapsular extension in patients who are thought
to have clinically localized PC, an MRI of the prostate gland using an endorectal probe can be obtained.11
CT scans are unable to diagnose extracapsular extensions and seminal vesicle invasion accurately,
and most are negative for metastasis, particular in those patients with lower PSA (<20) and Gleason Scores
(<8). Specialized CT scans are invaluable, however, in the planning of radiation treatment fields for those
men undergoing radiotherapy. Bone scans may also be utilized as a staging study, but like CT are
infrequently positive among men with localized disease.
It has clearly been shown since the 1980’s that MRI has limited value in detecting lymph node
metastases. Although it has a high specificity its sensitivity is quite low.12 However, the advent of Indium
111 capromab pendetine (ProstaScint®), a radiolabelled monoclonal antibody to prostate-specific
membrane antigen, may offer a means to detect such soft tissue PC metastases. When used properly, it can
be a valuable tool in staging the PC and in most studies thus far, its predictive ability before therapy was
superior to and shown to enhance the specificity of CT and MRI.13 Furthermore, since CT and MRI can
rarely detect disease upon relapse in low PSA settings (<1.0 ng/ml), this molecular imaging might offer the
best method to assess relapse.
The recent development of three-dimensional magnetic resonance spectra imaging (3D-MRSI) has
enhanced the diagnostic evaluation beyond the assessment of purely morphologic features. This methods
uses strong magnetic field and radio wave information to distinguish PC from healthy peripheral zone
tissue using the spectra information of choline, creatinine, citrate and various polyamines. In one study of
53 patients, the authors used the 3D-MRSI and MRI to localize the cancer to a sextant of the prostate with a
specificity of 91% and a sensitivity of up to 95%.14
With all of this said, prostate biopsy is still the gold standard for the diagnosis of PC. Transrectal
biopsy is a relatively simple office technique, usually performed without sedation or analgesia. In the
ultrasound-guided sextant biopsy, a biopsy gun is used to take a specimen from suspicious areas followed
by six tissue cores from the base, midzone, and apical areas of the right and left lobes of the gland. It is an
imperfect test as a large proportion of men with a negative initial biopsy but persistently high serum PSA
will have cancer diagnosed on subsequent biopsies.15 In one report, cancer was detected in 10% of second
biopsies, and in another study, the risk of detecting a clinically unimportant cancer was found to be 4%.16
Nevertheless, upon obtaining the biopsy, a pathologist will evaluate small suspicious areas and try
to differentiate carcinoma from typical and atypical cells. A Gleason grade is made from this analysis to
provide an index of prognosis and to guide local therapy. Primary and secondary scores are recorded and
combined to form a final Gleason grade. Grades of 2,3 and 4 usually suggest low-grade cancers, grades of
5,6 and 7 usually represent moderately differentiated cancers, and grades of 8,9 and 10 usually signify
high-grade cancers. Clinical staging often underestimates the extent of tumour actually found and the
probability of upstaging at the time of surgery is directly related to the Gleason score.17
One predictive model that utilizes a combination of Gleason grade, serum PSA and clinical stage
to predict the presence of organ-confined cancer (and thus the highest likelihood of cure with radical
prostatectomy or external beam radiation therapy) is the Partin model.18 Probability plots and nomograms
have been designed from this model to assist urologists in preoperative prediction of final pathological
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stage. They may be used to assess risk for metastasis and guide certain aspects of surgical management in
organ-confined disease. However, they are specific for the diverse ethnic mix of the United States and their
use has not been validated in most other countries despite the fact that they are still widely used.
In conclusion, the general approach used to detect PC has changed dramatically over the past few
decades, particularly with the advent of PSA testing which has been highly accredited for use in high PSA
ranges. However, while screening for the disease using PSA and DRE has significantly increased its early
detection, these strategies may not actually decrease mortality. Transrectal ultrasound, MRI, CT, and bone
scans can be used for further investigation, but the diagnosis of PC can only be made with a positive
biopsy. Finally, preoperative predictions of pathological stage may be made using nomograms and
probability plots derived from the Partin model.
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Feature Article
Human T-Lymphotropic Virus-I Infection and Adult T-cell Leukemia/Lymphoma:
Pathogenesis and Clinical Considerations
Brent Mollon, Meds 2010
The Human T-Lymphotropic Virus type I (HTLV-I) was the first human
retrovirus discovered and is implicated as the causative agent of Adult T-cell
Leukemia/Lymphoma (ATLL). The oncogenic properties of this virus are
believed to occur through the actions of the Tax protein, which has been shown
to act through direct protein-protein interactions or alteration of signalling
pathways to result in T-cell transformation, apoptosis inhibition and eventual
clonal expansion of infected cells. Clinically, ATLL can present in one of four
forms, termed acute, lymphomatous, chronic, and smoldering. Due to the
range in symptoms, definitive diagnosis is often based on immunophenotypic,
morphologic and serologic testing to note the characteristics of the cancerous
tissue and test for the presence of HTLV-I. Once diagnosed with ATLL, the
prognostic outlook of a patient may be influenced by many factors, such as the
form of ATLL or the types of proteins expressed by the cancerous cells. While
clinical trials are currently being conducted to determine the efficacy of new
therapies, an optimal therapy with a high cure rate does not exist to effectively
treat ATLL and HTLV-I infection.
This article has been reviewed by Dr. Faisal Rehman.
Introduction
In July of 1977, a 28 year old male sought medical attention for the presence of nodules on his
skin.1 A skin biopsy, lymph node biopsy, metatarsal bone biopsy, and examination of cells from the
peripheral blood revealed malignant convoluted T-cells. A diagnosis of cutaneous T-cell lymphoma was
made, and after treatment with concurrent whole-body electron-beam radiation therapy and combination
chemotherapy the cancer appeared to go into complete remission.1-3 Unfortunately, the disease recurred 18
months later with widespread systematic involvement. The patient was treated with the combination of
hydroxyldaunomycin, vincristine, the epipodophylotoxin VP-16, and cyclophosphamide. Once again,
treatment resulted in a complete remission, but only a few months later, the patient presented with
pulmonary infiltrates and brain lesions and soon after succumbed to the disease.1
During the above ordeal, two T-lymphoblast cell lines were established from this patient.1 From
these T-lymphoblast cell lines a type C primate virus (also known as a primate retrovirus) was isolated.1
This virus, known as the Human T-Lymphotropic Virus (HTLV-I), was the first human retrovirus to be
discovered.4 After its identification as a retrovirus, HTLV-I was identified as the causative agents in two
generally fatal diseases: HTLV-I associated myelopathy (HAM) and adult T cell leukemia/lymphoma
(ATLL).4-6
ATLL and HTLV-I
As noted in a review by Freedman & Harris7, ATLL has been defined as “… a peripheral T-cell
neoplasm associated with infection by the human T-lymphotropic virus, type I” (para. I), by the Revised
European-American Lymphoma and World Health Organization classifications.8-10 The terms leukemia
and lymphoma are used to distinguish the source of cancerous tissue. Leukemia is the result of
malignancies in hematopoietic stem cells which proliferate to replace regular stem cells within the bone
marrow.11 On the other hand, Non-Hodgkin’s Lymphomas originate from the malignant transformation of
lymphocytes that are differentiating within the peripheral lymphoid tissues.11
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Pathogenesis
ATLL manifests itself in only 2-5% of infected individuals, and usually becomes evident 20-30
years following initial infection.12 The virus has been reported to spread through sexual intercourse, blood
transfusions and through lymphocytes present in breast milk.13-15 It is estimated that this virus has infected
10 to 20 million individuals worldwide and is endemic in the Caribbean Basin, Southern Japan, parts of
Central and South America, Middle Eastern Asia, and Africa.16-17 Also, some regions in the United States
also have endemic levels of HTLV-I, although it is found primarily in African-American individuals.18
The transcriptional activator p40tax has been the focus of much research due to its implication as a
major oncoprotein of HTLV-1.4;19;20 For example, this protein has been present in leukemic cells and in
meylopathy.21-22 In addition, infection of CD4+ T-cells with retroviral vectors containing the Tax proteins
have been shown to result in T lymphocyte immortalization.17
The mechanisms by which Tax enables viral replication and latency are complex and are beyond
the scope of this paper. Nonetheless, as stated by Scadden and colleagues4, the ultimate result of the
actions of the Tax protein is “… to promote cell proliferation, induce genetic instability, and inhibit
apoptosis, leading to the persistent clonal expansion of infected cells and the promotion of oncogenesis,”.
Cellular Morphology
Genetically, all clones of the malignant T cell contain an integrated HTLV-I provirus23, with the T
cell Receptors genes all being clonally rearranged.24 In addition, deletion of tumour suppressor regions like
the p16 gene, or of a potential tumour suppressor gene located on 6q15-21, can be noted in some cell
lines.25;26 Lastly, trisomy or partial trisomy of chromosomes 3q, 6q and 14q has also been noted.7;27 The
form or extent of the genetic abnormalities present in these malignant cells may help dictate how aggressive
these malignancies will be.7 The malignant cells of ATLL also present with several morphological
abnormalities. For example, it is common to find cells with peculiar hyperlobated nuclei in a peripheral
blood test in patients presenting with leukemia.28 In the bone marrow, patchy infiltrates may be noted,
while infiltrates in the lymph nodes are more diffuse.7
Clinical Manifestations
The above cellular changes will eventually manifest themselves in one of the four distinct clinical
forms of ATLL.17 The symptoms of these forms, which are termed acute, lymphomatous, chronic or
smoldering, have been summarized in Table 1. Of the above, the acute form is most prevalent, occurring in
60% of patients with ATLL.7 In addition, 25% of patients presenting with the smoldering or chronic form
of the disease will eventually return to the acute form, perhaps the result of a genetic modification.29
Interestingly, the acute and lymphomatous forms of ATLL present with hypercalcemia, which is believed
to be paraneoplastic in origin.7

Diagnosis and Prognosis
Due to the numerous symptoms patients with ATLL may present with, correctly diagnosing this
disorder usually involves the noting of morphological characteristics of infected T cells,
immunophenotyping and the use of serologic tests to identify antibodies against HTLV-I.12 Serologic
diagnostic tests include the enzyme linked immunosorbent assay (ELISA) or particle agglutination.30;31
Polymerase Chain Reaction (PCR) based testing may be used to make a diagnosis of ATLL. This test has
the ability to distinguish between HTLV-I and HTLV-II, and can also quantify proviral load in the blood or
tumour cells.12;32;33 In addition to PCR, Western Blotting may also be used to confirm the presence of
HTLV-I or distinguish between HTLV type I and II.12;34
Many different factors have been identified which might determine how aggressive the cancer will
be. From a clinical point of view, one of the major factors dictating survival rate is the form of ATLL. As
summarized in Table 2, patients with Acute ATLL have the worst prognostic outlook, with a median
survival rate of 6.0 months and a 4 year survival rate of 5%.35 In addition to ATLL type, factors such as
increased provirus load or deletion/suppression of tumour suppressor genes like p16 may also worsen
prognostic outlook.7;17;25;36
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Table 1: Overview of the symptoms associated with the four clinical forms of ATLL. 7;12;17

Form
Acute

% of
Cases
60%

Lymphomatous

20%

Chronic

15%

Smoldering

5%

Signs and Symptoms
Lytic bone lesions
Hypercalcemia
Generalized lymphadenopathy (chronic lymph node enlargement)
Cutaneous lesions, similar to those noted in mycosis fungoides
CNS involvement in 10% of cases
Hepatosplenomegaly (enlargement of the liver and spleen)
Opportunistic Infections
Prominent Lymphadenopathy
Frequent blood, skin and bone lesions
Hypercalcemia is common
Absence of circulating tumour cells
Note: this form is a T-cell non-Hodgkin's lymphoma
Skin Lesions
Lymphocytosis (increased number of lymphocytes in the blood
stream)
Skin Lesions
Liver, lung and lymph node involvement
Absence of Hypercalcemia
No CNS or GI involvement
Normal blood lymphocyte counts
<5 percent circulating neoplastic cells
Absence of Hypercalcemia
Skin or Pulmonary Lesions

Table 2: Prognostic outlook for the four types of ATLL.35;37

Acute
Lymphomatous
Chronic
Smoldering

Duration of Survival (Median)
6.0 months
10.2 months
24.3 months
not reached after 13.3 months

4 Year Survival Rate (%)
5
5.7
26.9
62.8

Treatment
Different therapies aimed at managing ATLL have been studied within the clinical setting,
including: conventional chemotherapy for lymphoblastic leukemia or non-Hodgkin’s lymphoma, allogenic
hematopoietic stem cell transplantation, anti-retroviral drugs, monoclonal antibodies and arsenic trioxide
(for an overview of current therapies, see reference 35). While some therapies look promising, each form
of therapy tested has a unique set of strengths and weaknesses. Acknowledging such limitations,
researchers are now proposing a type-tailored approach to therapy.35 Using this protocol, patients would be
given different regimens depending on which form of ATLL they present with (see Figure 1).
Unfortunately, at this point in time, an affective treatment for ATLL, which essentially requires treatment
for both the cancer and the HTLV-I infection, does not exist.35
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Figure 1. Treatment
guidelines for ATLL, as
proposed by Bazarbachi
and colleagues.35

Conclusion
There has been a fair amount of biochemical and therapeutic work directed towards understanding
HTLV-I and treating the related ATLL. More research needs to be done in order to understand the factors
that contribute to viral latency in patients currently in remission. No treatment protocols thus far have been
effective in curing ATLL in a wide range of patients. Therefore, additional research should be conducted
to uncover new treatment regiments, as well as to establish the optimal combinations of current therapies to
treat each of the four forms of ATLL.
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Feature Article
48 Years and Counting
Gerald Schneiderman M.D., D. Psych., F.R.C.P.(C), F.A.P.A.
Member Bereavement Research Team, Hospital for Sick Children
Emeritus, Department of Psychiatry and Pediatrics, Hospital for Sick Children and Department of
Psychiatry and Pediatrics, University of Toronto
The purpose of this paper in writing a personal history is to help others define
for themselves their direction, the value of a solid professional and personal
life, ending up, regardless of the limitations in one’s life, with humility to find
out that giving back ultimately is one of life’s greatest rewards.
This article has been reviewed by Wendy Ng, Meds 2009.
My life and career in medicine have been an interesting journey. As a child I was greatly
influenced by a friend of my father who was a family doctor and who used to take me on with him when he
made housecalls. Later, as a teenager I got to know another family doctor who allowed me to assist him in
tonsillectomies. Then in high school I discovered that my greatest pleasure was talking and getting to know
people, which laid the seeds for my going into psychiatry.
The big secret in our family was that my father was unable to read or write, and this was a source
of pain for him. Probably for this reason, he wanted me to become a lawyer to help him grow his business.
Dad did allow me to make my own decision and although he was sad, I greatly respect his giving me the
right to do what I wanted to do. My development was also influenced by my mother, who was a voracious
reader, and this has also been part of my life. One of my greatest memories is of reading to them both in
the twilight of their lives, when my mother was virtually blind, a chapter of a book that I had written. 1
When I went to medical school 2 I disliked biochemistry and physiology, although today I wish I
had been more studious in these areas. Kreb’s cycle in my day was referred to as “crap's” cycle. In
disappearing from labs, I often went to the library and read psychiatry, which laid the groundwork for my
belief in a talking cure.
Several events in my internship were very meaningful and, as I look back on them, seem to have
helped shape my career. When I started out in obstetrics as part of my rotating internship at the Montreal
General Hospital, I really enjoyed talking to the patients who had problems with their lives after delivery. I
then went to the Montreal Children’s Hospital and while I was doing my in-patient work, I met a four-anda-half-year old boy named Jean Guy who had carcinoma. I taught Jean Guy to bounce a ball. Every
morning he was waiting for me to play. When I left to do internal medicine in my rotating internship and
came back at Christmas, I found out that Jean Guy had died. I left the big red ball that I had bought him at
the hospital, feeling very sad for him. However, I felt lucky to have known him and still always think of
his courage.
Another other experience I had at the hospital was when the son of family friends was dying of
leukemia and I tried to be supportive to them. I still remember the son asking me, when I went into his
room, how come his head was so big, which was a result of the medication. I learned then the importance
of listening and learning from children.
Starting out in psychiatry, I did believe with a passion that the talking cure was the answer.
Coming in the midst of the Kennedy era, I said to my friend, “We are going to change things.” Now that
the black box has been opened, the combination of neurobiology and the environment has added to my
understanding, although much is still to be learned.
In my career serendipity has played a large role. I moved from McGill to Toronto and started
working part-time at the Hospital for Sick Children. I was very sad about leaving Montreal because of the
changes that had occurred and stimulated by the FLQ crisis. Because of my training, I had, when asked,
the opportunity to do research on fatal genetic disorders, the lipid storage disorders which allowed me to
find a way to deal with my sadness and gain a commitment to move in this direction as well as clinical
practice. I wish that I had planned to look for a direction doing research earlier, for it has been vital to my
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growth in medicine. I also think a great gift would be for all to try and find a direction early, and consider
doing research. Studies have shown that individuals doing some research have particularly enjoyed their
careers in psychiatry.
Medicine is a labour-intensive career. When I was a resident the mantra of my teachers was
always to work harder and read more, and excellence only was considered normal. I have no regrets about
this mantra. However, the world is a big place and being a physician is not the only reality. It is the
doctor’s subjective reality and does not include the big picture. I urge everyone to take time to smell the
roses and find other interests to enlarge your view of this complex and interesting world.
Osler’s quote of treating the patient who has the illness is very important. It also applies to
physicians who have to heal themselves. Don’t forget that your family at dinner is probably one of the
most exciting activities for you. I have had the privilege of working with 3 medical families and seeing the
tragedies of alcoholism, drug addiction, marital disharmony and financial ruin, to name a few, far too often.
I have discovered that a great source of my family tradition 4,5 through my grandchildren has been an
excitement that I cannot put into words and provides hope in the succeeding generations. Being called
Grampa and spoiling them, allowing my children to pick up the responsibility, is sheer joy.
I have contributed to medical organizations, including human rights, which has been my interest
since my undergraduate days, where I was involved in World University Service. This has been stimulated
by my commitment of coming from an immigrant family and enunciated by Dad, who insisted that you
never forget where you came from. The problem with medical politics, although one makes a contribution,
is that much of the time it is organizational and has the feeling that it is sometimes not real. So I have
found another source to add to my reality which has been establishing a lecture in human rights at the
University of Toronto and becoming involved in International Development Enterprises, 6 which is a nonprofit organization that attempts to promote agriculture development through water in third world countries.
How I got started in this was good fortune. My classmate, Paul Polak, has been coming to
Homecomings talking about his organization and at our last Homecoming, I said, “Paul, you have done it. I
would like to contribute.” The richness of watching his creativity 7, hearing about his organization and his
ability to see and plan and create has led to an enterprise which now has an annual budget of $10 million
and hopefully will increase over the years.
As I sit writing in the airplane on my way to an International Development Enterprises board
meeting, I think about many things in life that have been good to me. As I hope for all of you that you
remember to look after yourselves, a steadying force for me has always tried to keep one foot on the
ground. I will always remember THE professor at the University of Toronto, the late Robin Hunter, saying
to me, “Schneiderman, when are you going to stop pushing water uphill?” I find that my growth has led to
humility and my admission was very comforting. I don’t know everything about everything.
We are fortunate to have medicine as a career. The benefits of helping patients have been one of
life’s greatest rewards.
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